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cFTOE cerebral fractional oxygen extraction
CL clearance 
CO cardiac output 
Css  steady state plasma concentration
ELBW extremely low birth weight, < 1000 g
GA gestational age 
GFR glomerular filtration rate
GOF goodness-of-fit 
HD haemodynamic/haemodynamics
HR heart rate 
IVH intraventricular haemorrhage
LLOQ lower limit of quantification
LV left ventricle 
LVO left ventricular output
MAP mean arterial blood pressure
NICOM non-invasive electrical cardiometry
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PK pharmacokinetic/pharmacokinetics
PKPD pharmacokinetic-pharmacodynamic
PLCS post-ligation cardiac syndrome
PMA postmenstrual age
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1. INTRODUCTION 
The neonatal period, covering only the first 28 days after birth, includes major 
developmental differences. As premature birth is the main reason for critical 
illness within this period, neonatologists are confronted with a more than ten-fold 
weight range as well as variable gestational age (GA), postnatal age (PNA) and 
dysmaturity. Furthermore, in addition to rapid maturational changes, critical illness 
and intensive and invasive therapies increase the physiological variability. 
We use many medications in neonatal intensive care units (NICU), at least up 
to 65% of them off-label (Lass et al. 2011; Nir-Neuman et al. 2018). Preterm 
neonates – the most vulnerable paediatric age group – have the highest exposure 
to drugs that are insufficiently documented (Kimland et al. 2012; Lass et al. 
2011). Difficulties interpreting the sparse evidence also lead to large differences 
in drug prescribing practices and local administration protocols between NICUs 
(Batton et al. 2013, 2016; Burns et al. 2016; Sehgal et al. 2012; Stranak et al. 
2014; Wong et al. 2015). 
The same goes for cardiovascular drug therapies in neonates. There is little 
evidence for which vasoactive medications to use in which patient and when, at 
what dose to start, how to titrate the drug, and which parameters to monitor 
(Barrington 2008; Evans 2006; Kluckow et al. 2008). Administration of inotropes 
is based on a variety of clinical assessments, including low blood pressure (BP), 
poor cardiac function or low cardiac output (CO), poor peripheral perfusion or 
decreased urine output, and lactic acidosis, all considered to be indicators of 
circulatory failure. Neonatal cardiovascular physiology has many important unique 
features; thus, the dosing and presumptive effects of therapeutic interventions 
cannot be extrapolated from adult studies. 
Pharmacokinetic-pharmacodynamic (PKPD) modelling is an important tool 
in clinical pharmacology research, and the population approach is suitable for 
sparse data in terms of the number of samples per subject, as is often the case in 
neonates. The identification of predictive developmental and non-maturational 
covariates provides the scientific basis for rational and individualised, patient-
tailored dosing schemes. Without an adequate understanding of the PKPD 
relationship, its variability at the inter- and intra-individual levels, and how it 
changes during the rapid maturation in the neonatal period, it is possible that 
inappropriate doses will be studied and potentially useful drugs will be discarded 
because of inappropriate dosing. It has recently been shown that failure to 
properly appreciate dose-response relationships has been a leading factor in 
problems with generating information useful for licensing paediatric medicinal 
products (Jadhav et al. 2010). 
It is necessary to study the pharmacokinetic (PK) and pharmacodynamic (PD) 
properties of medications in the specific neonatal populations for which they are 
used. The present thesis concentrates on two particular situations and their 
respective populations: transitional circulation in critical illness within the first 
days of life and post-ligation cardiac syndrome (PLCS) prevention. 
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We started with finding the optimal dosage of milrinone for our study patients 
according to the best knowledge about the PK of the drug and the peculiarity of 
the population of neonates undergoing patent ductus arteriosus (PDA) ligation. 
The dosing scheme was carried forward to a prospective study in this population 
to get more precise information about the PK of milrinone in neonates of different 
ages. Finally, we conducted a prospective PKPD study of dobutamine to describe 
concentration-related effects on haemodynamics (HD) in critically ill neonates 
within the first days of life.  
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2. REVIEW OF LITERATURE 
2.1 Transitional circulation of a newborn 
The neonatal cardiovascular system has many special characteristics that make 
the HD compromise of a newborn different from that of other paediatric and adult 
populations. The function of the newborn heart is characterized by a relatively 
high resting CO with little contractile reserve due to the presence of non-contractile 
fibrous tissue, which results in high sensitivity to any increase in afterload. 
Newborn babies can increase their CO by tachycardia, but severe tachycardia may 
result in decreased stroke volume. Neonatal vasoregulation is characterized by a 
high concentration of endogenous catecholamines balanced by activated 
vasodilating systems such as prostaglandins, bradykinin and nitric oxide (Toth-
Heyn et al. 2012). The developmentally regulated differences in vascular α- and β-adrenoreceptor (AR) expression affect the cardiac and peripheral vascular 
response (Felder et al. 1983; Noori et al. 2012; Vapaavouri et al. 1973). 
Preterm babies tend to have a hypoperfusion reperfusion cycle over the first 
24–48 hours. The hypoperfusion seems to relate to maladaptation to high vascular 
resistance, while the reperfusion relates to loss of vascular resistance (Evans 
2006, 2009). Factors probably aggravating hypotension and its consequences on 
systemic and cerebral blood flow (CBF) in preterm infants include hypovolaemia, 
PDA, sepsis, persistent pulmonary hypertension of the newborn (PPHN), and 
severe respiratory distress. 
 
 
2.2 Patent ductus arteriosus and  
cardiovascular response after ligation 
The ductus arteriosus is a physiological structure shunting blood from the 
pulmonary artery to the descending aorta during foetal life (Gentile et al. 1981). 
The ductus arteriosus closes in the majority of term infants within the first 
48 hours after birth. In about 50–70% of extremely low birth weight (ELBW) 
infants, it remains open and may cause various clinical problems (Clyman et al. 
2012; Koch et al. 2006; Nemerofsky et al. 2008). Today, no consensus exists on 
the definition of hemodynamically significant PDA, and it remains difficult to 
identify the patients most likely to benefit from surgical duct closure. Obser-
vational studies show a 10–21% incidence of surgical closure (Boghossian et al. 
2017; Hagadorn et al. 2016; Lokku et al. 2016; Weinberg et al. 2016). Surgical 
ligation of a PDA leads to sudden changes in cardiovascular physiology, 
specifically a rise in left ventricular (LV) afterload and a fall in LV preload, with 
a resulting sudden drop in LV output (LVO) (El-Khuffash et al. 2012; Jain et al. 
2012; Noori et al. 2007). Prospective observational studies in human neonates 
have demonstrated declining LV performance in the immediate postoperative 
period, coinciding with decreased pulmonary venous return and increased SVR. 
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The clinical effects of this low CO state usually become apparent at 6–12 hours 
after ligation (McNamara et al. 2010; Teixeira et al. 2008). 
Given that the effect of preload change is greatest within the first 1–2 hours 
after surgery, this change is unlikely the major determinant of the deterioration 
in clinical condition. An increase in the slope of the inverse relationship between 
end-systolic wall stress and the velocity of circumferential fibre shortening 
suggests that changes in myocardial performance are related to LV afterload. The 
timing of clinical deterioration (8–12 hours after surgery) coincides with the 
period of maximal afterload exposure (McNamara et al. 2010). Infants weighing 
<1000 g are at the greatest risk of HD compromise, which is biologically plausible, 
considering that the preterm myocardium is not conditioned to handle substantial 
changes in either preload or afterload. A prospective study using non-invasive 
electrical cardiometry (NICOM) to measure hemodynamic changes during 
surgical ligation of PDA in very low birth weight (VLBW) infants concludes that 
reduced stroke volume and elevated vascular resistance contribute to the major 
hemodynamic aberrations in VLBW infants receiving PDA ligation surgery (Lien 
et al. 2015). 
The presence of prolonged left-to-right shunting across the PDA leads to 
altered pulmonary compliance. Improvement in lung compliance has been shown 
with successful medical as well as surgical PDA closure (Balsan et al. 1991; 
Farstad et al. 1994; Stefano et al. 1991; Szymankiewicz et al. 2004). If dynamic 
lung compliance improvement is coupled with an increase in tidal volume and 
minute ventilation, these changes may lead to lung overdistention, possibly further 
compromising vena cava and pulmonary venous flow, leading to impaired 
ventricular filling and contributing to decreased CO (El-Khuffash et al. 2013). 
Changes in cardiopulmonary physiology after surgery may lead to a severe 
HD and respiratory deterioration – PLCS, defined as systolic BP below the 3rd 
percentile expected for GA requiring one or more cardiotropic agents accompanied 
by ventilation or oxygenation failure – in 10–40% of infants (Jain et al. 2012; 
Teixeira et al. 2008). PLCS is related to an increase in mortality (33% vs 11% 
compared with controls) (Harting et al. 2008). Risk factors reportedly associated 
with PLCS include earlier age at ligation, lower BW, younger GA, large PDA 
and the level of preoperative cardiorespiratory support (Harting et al. 2008; 
McNamara et al. 2010; Mertens et al. 2011; Moin et al. 2003; Noori et al. 2007, 
2015; Teixeira et al. 2008; Ulrich et al. 2018). The definition cited above may be 
too restrictive, however, as PLCS is likely a spectrum disorder of varying severity, 
with some infants developing profound hypotension and others suffering 
exclusively from ventilation and oxygenation failure (El-Khuffash et al. 2013). 
PLCS typically occurs between 6–12 hours after surgery; therefore, there is a 
temporal window for early intervention with inotropic therapy (Jain et al. 2012; 
McNamara et al. 2010; Teixeira et al. 2008). Left ventricular output (LVO) 
<200 ml/kg/min at one hour after PDA ligation has been found to be a sensitive 
predictor of systemic hypotension and the need for inotropes (Jain et al. 2012). 
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2.3 The use of inotropes in neonates 
2.3.1 Current practice 
Inotropic treatment is started in response to low BP, low CO or signs of deficient 
tissue perfusion in critically ill neonates. The challenge for clinicians in the NICU 
is to identify the aetiology of the hemodynamic changes, decide if the changes 
are transitionally appropriate or not, and based on this understanding, tailor the 
treatment regimen for the patient.  
Arterial hypotension during the early postnatal period is common in preterm 
infants and sick term neonates. Low tissue perfusion as a consequence of hypo-
tension and failure of cerebral vascular auto-regulation are suggested as important 
risk factors for postnatal brain injury and neonatal morbidity of preterm and sick 
term neonates, including multi-organ dysfunction and acquired brain lesions 
(Evans 2009; Osborn et al. 2003; Volpe 2001). However, the threshold of 
treatment to improve short- and long-term outcomes has not been established 
(Laughon et al. 2007). 
Studies in Europe, North America, and Australia highlight variable practices 
across countries and continents with respect to which patient, when and how to 
treat with which inotropic drugs (Batton et al. 2013, 2016; Burns et al. 2016; 
Sehgal et al. 2012; Stranak et al. 2014; Wong et al. 2015). An observational study 
in extremely preterm infants with GA less than 27 weeks reports that 55% of this 
population received any anti-hypotensive therapy and 28% received vasoactive 
drugs within the first 24 hours of life (Batton et al. 2013). A recent Norwegian 
population database study indicates that 2.7% of all NICU patients received 
inotropes at some point during their NICU stay, including 28% and 4.1% of 
neonates born at <28 and <36 weeks of GA, respectively, and 13% of <1,500 g 
infants (Burns et al. 2016). Cardiovascular drugs were the second most 
commonly used medication group after anti-infectives in extremely and very 
preterm (GA <32 weeks) neonates in Estonian neonatal units: 59% and 54% of 
extremely low GA (<28 weeks) neonates received dobutamine and dopamine, 
respectively (Lass et al. 2011). According to a study including 1507 extremely 
low GA (23–27 weeks) newborns, 73–93% received any treatment for 
hypotension and 25–52% were treated with vasopressors during the first week of 
life. The treatment of shock, cardiovascular instability or low systemic flow in 
neonates and preterm infants is mainly empirical and not based upon evidence 
obtained from controlled prospective clinical trials. The decision to provide 
treatment is associated more strongly with the centre where care was provided 
than with infant attributes (Laughon et al. 2007).  
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2.3.2 Cardiovascular drugs used to treat acute haemodynamic 
compromise in neonates 
Clinical outcome-based data on the significance of different inotropes to prevent 
sequelae of hypotension/ hypoperfusion, including cerebral morbidity, are limited 
and controversial. The inotropes mainly used in the short-term treatment of 
systemic hypotension in preterm and term infants are dopamine and dobutamine 
(Burns et al. 2016; Dempsey et al. 2019). 
 
Dopamine is a naturally occurring precursor of norepinephrine and has specific 
dopaminergic actions in addition to well-recognised α- and β-adrenergic effects 
(Keeley et al. 1988). At moderate doses (5–10 μg/kg/min), dopamine increases 
contractility and heart rate (HR) by stimulating the cardiac β1-, β 2-, and α1-AR 
and the dopaminergic receptors; at high doses (≥10–20 μg/kg/min), dopamine also 
increases systemic and probably pulmonary vascular resistance by stimulating 
vascular α1-AR (D’Orio et al. 1984; Goldberg 1972). Approximately 50% of the 
positive inotropic effect of dopamine is caused by the dopamine2-receptor 
stimulation-induced release of norepinephrine stored in the peripheral sympathetic 
nerve endings in the myocardium. Because myocardial norepinephrine stores get 
depleted within 8 to 12 hours, dopamine, especially in the preterm neonate with 
decreased myocardial norepinephrine stores, is a less effective positive inotrope 
in the long run compared with epinephrine (Seri 1995). Because of maturational 
differences in the expression of the α- and β-AR in neonates, without AR down-
regulation, clinical manifestations of vascular α-AR simulation (e.g. increase in 
SVR) become apparent even at low-to-medium doses (Davies et al. 1984; Felder 
et al. 1983; Ruffolo et al. 1986; Seri 1995, 2006; Seri et al. 1984; Vapaavouri et 
al. 1973). Therefore, in neonates with escalating dopamine infusion, the pattern 
of receptor stimulation is first dopaminergic, then α-adrenergic, and finally β-
adrenergic. Thus, peripheral vasoconstriction dominates over the inotropic effect 
when dopamine is given (Seri 1995, 2006; Seri et al. 1984). 
 
Dobutamine is a synthetic analogue of dopamine and isoprenaline 
(hydroxyphenyl-isobutyl-dopamine), designed to increase contractility without 
significant tachycardia or vasodilation (Tuttle et al. 1975). However, unlike 
dopamine, its action is independent of endogenous norepinephrine release, and it 
does not have any dopaminergic activity. It stimulates both α- and β-AR, with a 
pronounced relative β1 cardio selective action and less affinity for peripheral α1- 
and β2- receptors. (Keeley et al. 1988)  
It has been suggested that dobutamine offers the same inotropic effects as 
dopamine without the tendency for peripheral vasoconstriction (Gupta et al. 
2014). The expected net effect is increased systemic and local blood flow without 
a significant change in BP (Cheung et al. 1999). Dobutamine is the drug of choice 
to increase CO in neonates with myocardial dysfunction. However, its effect on 
organ blood flow may be variable and seems to depend on the underlying patho-
physiology. Thus, the hemodynamic response to dobutamine makes it suitable 
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for clinical situations in which poor myocardial contractility with unchanged or 
increased SVR is the primary cause of the cardiovascular compromise, such as 
perinatal asphyxia or a very preterm neonate with poor systemic blood flow and 
vasoconstriction (Noori et al. 2012). In contrast, in conditions with low SVR (e.g. 
vasodilation), such as those seen in the early stages of septic shock or in a very 
preterm neonate with vasodilatory shock during the transitional period, dobutamine 
is not appropriate (Evans 2006). However, the addition of dobutamine to dopamine 
in patients with cardiovascular compromise caused by impaired myocardial 
function and vasodilation is a reasonable approach and may be effective. An 
additional effect of dobutamine on increasing CO has been demonstrated in 
hypotensive preterm infants receiving dopamine (Lopez et al. 1997). 
There is considerable controversy as to whether dopamine or dobutamine 
should be the first-line pharmacological agent for the treatment of neonatal 
hypotension. Proponents of dopamine often argue that it brings about a faster and 
more effective increase in BP. This is not surprising, since it is a potent vaso-
constrictor. However, proponents of dobutamine argue that intense vasocon-
striction by dopamine may further compromise tissue perfusion because of 
decreased blood flow (Gupta et al. 2014). Randomized controlled trials of 
dopamine versus dobutamine in preterm neonates have demonstrated that 
dopamine is more effective in increasing BP, while dobutamine increases CO 
(Osborn et al. 2002; Roze et al. 1993). In a study of preterm neonates with low 
systemic blood flow within 24 hours of birth, dobutamine resulted in a signi-
ficantly greater increase in superior vena cava flow (SVCF) and right ventricular 
output (RVO), while dopamine resulted in a significantly greater increase in BP. 
Overall 40% of neonates failed to increase or maintain SVCF in response to either 
inotrope, and no significant differences in mortality or morbidity were found 
(Osborn et al. 2002). 
 
Epinephrine has combined α- and β-AR agonist effects. At low doses, it is a 
potent inotrope, chronotrope, and systemic and pulmonary vasodilator. At higher 
doses, it has differential effects on the systemic and pulmonary circulation, 
increasing systemic pressure more than pulmonary pressure (Barrington et al. 
1995). Epinephrine is frequently used in neonates for the treatment of hypo-
tension and pulmonary hypertension, although data on the cardiovascular effects 
of epinephrine in neonates is limited (Zaritsky et al. 1984). A randomized con-
trolled clinical trial of dopamine versus epinephrine demonstrated that the two 
medications have similar efficacy in improving BP and increasing CBF in hypo-
tensive preterm infants (Pellicer et al. 2005). However, patients randomized to 
epinephrine more frequently developed increased serum lactate levels, inde-
pendent of the improvement in their hemodynamic status, and hyperglycemia 
requiring insulin treatment. (Valverde et al. 2006) These metabolic effects are 
most likely explained by the drug-induced stimulation of β2-AR in the liver and 
skeletal muscles, resulting in decreased insulin release and increase in glyco-
genolysis, leading to an increase in lactate production, respectively (Noori et al. 
2012). 
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Norepinephrine is an endogenous catecholamine that is released from adrenergic 
nerve endings. It has strong stimulating effects on α- and β1-AR and weaker 
effects on β2-AR. Norepinephrine has more potent α-mediated effects compared 
with epinephrine, which results in an increase in SVR and BP. While it is seldom 
used, it may be useful to improve BP and urine output during neonatal septic shock 
in preterm and term infants unresponsive to dopamine and dobutamine (Rizk et 
al. 2018; Tourneux et al. 2008). Norepinephrine might have a role in treating 
circulatory failure in severe PPHN due to a reported pulmonary vasodilatory 
effect (Tourneux et al. 2008). A retrospective study looking at norepinephrine use 
in preterm neonates over a 10 year period reported effectiveness in increasing BP 
with no major side effects (Rowcliff et al. 2016). 
 
Milrinone is a selective phosphodiesterase type III inhibitor that raises intracellular 
cyclic adenosine monophosphate levels, which increases intracellular calcium 
concentrations and promotes contractile protein phosphorylation, resulting in 
improved systolic cardiac contractility, diastolic cardiac relaxation, and vascular 
relaxation. As milrinone has inotropic effects independent of β-AR stimulation, 
it does not rise myocardial oxygen consumption (Honerjäger et al. 1992; Yano et 
al. 2000). 
Its usefulness in treatment of low CO states has been well demonstrated in 
adults. The drug has certain advantages, such as fewer tachyarrhythmias and the 
absence of tachyphylaxis when compared to dobutamine (Copp et al. 1992; Rettig 
et al. 1989). In a double-blind, randomised, placebo-controlled trial, 90 high-risk 
preterm infants born at <30 weeks of GA were randomised within the first 6 hours 
of life to receive milrinone (loading dose 0.75 μg/kg/min for 3 h, then main-
tenance 0.2 μg/kg/min until 18 h after birth) or a placebo to prevent low systemic 
blood flow. The primary outcome was maintenance of SVC flow >45 ml/kg/min 
through the first 24 hours of life. No difference in preventing low systemic blood 
flow between the two groups was found. Furthermore, milrinone-treated subjects 
had an increased incidence of tachycardia, low BP, and hemodynamically 
significant PDA (Paradisis et al. 2009). However, in another small pilot study in 
term infants with pulmonary hypertension, milrinone was reported to improve 
oxygenation and pulmonary and systemic HD in patients with suboptimal 
response to inhaled nitric oxide (McNamara et al. 2006). Administration of 
milrinone to neonates with low CO after surgical closure of PDA may lead to 
improved postoperative stability (Jain et al. 2012).  
 
Arginine vasopressin is a neuropeptide hormone secreted by the posterior 
pituitary that regulates sodium homeostasis and serum osmolality. Vasopressin 
exerts a direct vasoconstrictive effect by acting on the V1 receptors that are 
predominantly found on vascular smooth muscle cells and the myocardium. In 
addition, it has vasodilatory effects in cerebral and renal arterioles by simulation 
of V2 receptors. Currently, vasopressin and its analogue, terlipressin, are 
increasingly being used as a rescue therapy for hypotension refractory to high-
dose catecholamine and corticosteroids in neonates with sepsis, cardiogenic 
shock, necrotizing enterocolitis, non-septic shock with acute renal injury, and 
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systemic inflammatory response syndrome following surgery (Bidegain et al. 
2010; Filippi et al. 2008; Leone et al. 2008). One study of vasopressin for refractory 
hypotension in 22 extremely low‐birthweight infants suggests that low‐dose 
vasopressin therapy should be considered as a rescue therapy when high‐dose 
catecholamine therapy and/or steroid administration do not produce a sufficient 
increase in BP (Ikegami et al. 2009). A recent pilot study in 20 very preterm 
neonates compared vasopressin to dopamine during the first 24 hours of life. Both 
agents resulted in a similar increase in BP, but less tachycardia was seen in the 
vasopressin group (Rios et al. 2015). 
 
Levosimendan is a calcium sensitizer and inodilator. It binds to cardiac troponine 
and enhances the sensitivity of contractile myofilaments to intracellular calcium 
in the cardiac muscle cell, thus improving myocardial contractility. It also 
activates the sarcolemmal potassium-sensitive adenosine triphosphate channels 
of vascular smooth muscle cells, which has a vasodilatory effect (Egan et al. 2006; 
Udvary et al. 1995). Levosimendan has been used in neonates, particularly in 
infants undergoing cardiac surgery, and initial reports are encouraging (Lechner 
et al. 2012). A small phase 1 study indicated that it may be superior to milrinone 
in this context (Pellicer et al. 2013). Improved tissue oxygenation measured with 
near-infrared spectroscopy (NIRS) has been reported in a cohort of neonates 
undergoing cardiac surgery (Ricci et al. 2012). While the drug shows promise, its 
use may be restricted to cases of shock with myocardial dysfunction as a major 
contributor, but as there are no reliable data on levosimendan in preterm neonates, 
such a use cannot be recommended (Bhat et al. 2015; Dempsey et al. 2019). 
Despite their ongoing use, there is surprisingly very little neonatal PK and PD 
data available on the drugs discussed above (Dempsey et al. 2019). 
 
 
2.4 Developmental pharmacology  
Children differ from adults in their response to drugs. These differences may be 
caused by changes in the PK and/or PD between children and adults and may also 
vary among children of different ages. The PK of a drug includes the processes 
of absorption, distribution, metabolism and elimination, whereas the PD comprises 
the physiological and biological response to the administered drug and, therefore, 
may represent both efficacy and safety measures. While a child grows, elimination 
pathways and the function and expression of receptors and proteins mature, 
which can be referred to as “developmental changes” in childhood. Develop-
mental pharmacology aims to understand the impact of growth and maturation 
on drug disposition and action in the neonatal and paediatric population. The 
maturation rates of developmental changes vary between the distribution, 
elimination and effect pathways and often do not correlate solely with increases 
in the body weight or age of the child. The question is therefore how to obtain 
data in children that contribute to understanding of these developmental changes, 
ultimately resulting in evidence-based dosing regimens for drugs in children (De 
Cock et al. 2011). 
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2.4.1 Rapid changes in neonatal physiology affecting pharmacokinetics 
The rate of maturation of PK processes is most pronounced in the first 2 years of 
life.  
 
Distribution is dependent on the extent of protein binding, pH, systemic and 
regional blood flow, permeability of natural “barriers” (e.g. blood–brain, placenta), 
and body composition. Clearly, these covariates will display both inter- as well 
as intra-patient variability, partly explained by maturational changes or disease-
related differences (Batchelor et al. 2015). 
Age-dependent maturational changes in body composition change the 
physiological spaces into which a drug will distribute. Neonates and young infants 
have a proportionally higher amount of body water per weight when compared to 
children and adults, and preterm neonates have an even higher value when 
compared to term neonates (Allegaert et al. 2014, 2018; Kearns et al. 2003). The 
total body water content is about 80% to 90% of total body weight in preterm and 
70% in term neonates, with a progressive decrease to about 60% at the end of the 
first 1–2 years and subsequent stabilization throughout childhood (Friis-Hansen 
1971). This pattern is similar for extracellular water content, starting at 40% of 
body weight and decreasing to about 25% to 30% at the end of infancy. In preterm 
neonates weighing less than 1,500 g, postnatal weight loss up to 10% of birth 
weight (BW) within the first 3 days of life occurs due to isotonic dehydration of 
the extracellular volume (Bauer et al. 1989). 
Further, the presence of a PDA has been associated with an increase in the 
distribution volume of water-soluble compounds in preterm neonates. In an ibu-
profen PK study in preterm neonates receiving the medication for PDA closure, 
a decrease in the central compartment volume of distribution was most pro-
nounced in patients with a closing duct (Van Overmeire et al. 2001). The same 
tendency has been shown with other drugs (Gal et al. 1991; Thalji et al. 1980; 
Watterberg et al. 1987; Williams et al. 1997). 
For the lipid compartment, the trends are more complex, with an initial 
increase from 10% to 15% of body weight at birth to 20% to 25% at the end of 
infancy, and a subsequent decrease back to 10% to 15% until adolescence 
(Allegaert et al. 2014, 2018; Friis-Hansen 1971). 
These developmental changes in body composition have an impact on both 
water- and lipid-soluble medications. A decreased volume of distribution from 
neonates throughout childhood has been shown with aminoglycosides and 
acetaminophen (Allegaert and van den Anker 2017; Allegaert et al. 2011, 2015; 
Pacifici 2009). Increase in the volume of distribution in the first year of life has 
been shown with propofol (Allegaert, de Hoon et al. 2007). 
Drug distribution is also influenced by protein binding. Compared to adults, 
infants and children have lower concentrations of the most relevant plasma 
binding proteins such as albumin, α-1 acid glycoprotein, or plasma globulins. 
Because protein concentrations reach adult values in infancy, this effect is likely 
to be most pronounced in neonates and young infants. In addition to the absolute 
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values or concentrations of proteins, competitive binding with endogenous 
compounds (bilirubin, free fatty acids) may further affect the binding capacity 
(van den Anker et al. 2018; Roberts et al. 2013; Smits et al. 2012). Clinical 
implications of alterations in the extent of protein binding of a drug are most 
relevant for those drugs that are highly protein bound and also have a narrow 
therapeutic index (Roberts et al. 2013). Reduced protein binding increases the 
free concentration and the free fraction of drugs, thereby enhancing the capacity 
of the active drug to diffuse more easily to other compartments. This will result 
in more interaction with receptors, but it also will increase the clearance rate of 
the drug (van den Anker et al. 2018). 
 
Drug metabolism and excretion is a complex process involving different tissues 
with regional blood flow, the extraction rate, and the intrinsic drug-metabolizing 
enzyme specific capacity, and all these aspects may display age-related differences. 
Thinking of drug metabolism as being low in neonates and rising throughout 
infancy, early childhood, and prepuberty to reach adult levels in puberty is too 
simplistic (Hines 2007). 
Elimination of drugs by the kidneys is dependent on glomerular filtration rate 
(GFR), tubular excretion, and tubular reabsorption. From a maturation stand-
point, each of these processes exhibits an independent rate and pattern of devel-
opment (van den Anker et al. 2018). Nephrogenesis starts in the embryo at 
approximately week 5, and nephrons become functional by week 8; it is complete 
at gestational week 36, when there are approximately 1,000,000 nephrons in each 
kidney (Anderson et al. 2008). The kidneys are anatomically and functionally 
immature at birth. The GFR is reported to double by one week of age (Chen et al. 
2006). Rhodin et al. describe the maturation of the GFR with a consistent relation-
ship with postmenstrual age (PMA) from early prematurity to adulthood (Rhodin 
et al. 2009). Tubular secretory and reabsorptive capacity appear to mature at much 
slower rates compared to GFR, and thus, they do not have a significant impact on 
elimination during the neonatal period (Halkin et al. 1978). 
These age- and size-related developmental changes describe only a part of the 
inter-subject variability of PK parameters in neonatal populations. Genetics, 
comorbidity, and environmental issues further interact with these developmental 
changes (Blake et al. 2006; Leeder et al. 2010; Linakis et al. 2018). 
 
2.4.2 Pharmacokinetic/pharmacodynamic modelling  
in paediatric populations 
Population PKPD modelling using mixed effects models provides an opportunity 
to study between-individual variability in paediatric drug responses among children 
and neonates. Covariate analysis allows us to discover parameters that explain 
the predictable part of the between-individual variability. The main explanatory 
covariates in paediatric populations are size and age, representing growth and 
development, and varying in a range far greater than that seen in adults.  
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Size standardisation is achieved using allometric scaling, a mechanistic approach 
that has a strong theoretical and empirical basis (Anderson et al. 2006).  
The factor for size (Fsize) for total drug clearance may be expected to scale to 
weight with an allometric exponent of 3/4 (Equation 1). It is useful to report 
parameter values in terms of a standard subject (Wst), and this holds most 
obviously for size (Holford 1996). 
 
 𝐹 =  Equation 1 
 
For ease of comparison with other results, the size factor is usually standardized 
to a value of 70 kg (Anderson et al. 2011). When other size standards (e.g. 1 kg) 
have been used for children, comparison with adult estimates was not readily 
obvious. (Anderson et al. 2011; Knibbe et al. 2009; Su et al. 2010). 
Age is used to describe maturation processes that are independent of size but 
are associated with the passage of time. The quantitative models (linear, expo-
nential, first-order, variable slope sigmoidal) used to describe this maturation 
process vary depending on the span of the ages under investigation (Anderson et 
al. 2006). Maturation of clearance begins before birth, which means that post-
conception age is a better predictor of the state of maturation than PNA. However, 
for pragmatic reasons, PMA has been recommended for studies of biologic age 
(Engle et al. 2004). The sigmoid hyperbolic or Hill model has been found useful 
for describing this maturation process (Fmat; Equation 2) (Anderson et al. 2011), 
 
 𝐹 =   Equation 2 
 
where Hill is the sigmoidicity coefficient and PMA50 is the PMA when the 
maturation of clearance reaches 50% of adult values (Germovsek et al. 2017). 
The utility of paediatric PK models can be increased by using a standardized 
approach to scaling: a suggested method for scaling clearance is a combination 
of allometric weight scaling with a sigmoid function to account for organ matura-
tion (Germovsek et al. 2017). Extrapolations of developmental covariate models 
between drugs sharing an elimination pathway would also be useful for paediatric 
dose adjustment, but this applies only in specific cases, depending on a drug’s 
extraction ratio, unbound fraction, type of binding plasma protein, and the 
fraction metabolized by the isoenzyme pathway for which clearance is scaled 
(Brussee et al. 2019; Calvier et al. 2018). 
The nonlinear change in GFR with growth and age is also described by 
allometric scaling to bodyweight with coefficient of 0.75 or 0.632 and sigmoid 
Emax model describing the maturation with PMA. (Rhodin et al. 2009) 
Additional to the growth and maturation taking place since conception, there 
may also be changes in drug clearance related to birth. Transition from the 
intrauterine to the extrauterine environment is associated with major changes in 
blood flow. There may also be an environmental trigger for the expression of 
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some metabolic enzyme activities (Anderson et al. 2011). PNA can be used to 
identify and describe effects beyond those predicted from PMA alone (Allegaert, 
Peeters et al. 2007). Two models are proposed that could be used to investigate 
this PNA effect (Fbirth) (Anderson et al. 2011). The first one is an asymptotic 
exponential model (Equation 3): 
 
 𝐹 = ∙ ∙ ( )  Equation 3 
 
where FBmax is the fractional increase relative to the value at birth and TB50 is the 
half-time to achieve 50% of this relative change. Fbirth approaches an asymptote 
of 1 as the baby gets older. The second is a sigmoid Emax model (Equation 4): 
 
 𝐹 = ∕  Equation 4 
 
where additional parameter (FBHill) allows greater flexibility with the rate of 
change of maturation after birth. This factor for a change associated with PNA 
after birth (Fbirth) can be included in the descriptors of parameter (e.g. CL) 
maturation (Equation 5) (Anderson et al. 2011): 
 
 𝐶𝐿 = 𝐶𝐿 ∙ 𝐹 ∙ 𝐹 ∙ 𝐹  Equation 5 
 
This should be used a priori as a ‘base’ approach, allowing the effects of age and 
size to be delineated from other patient-specific factors, such as disease state and 
organ (dys)function.  
Significant progress has recently been made on paediatric PK modelling; a 
greater emphasis now needs to be placed on PD modelling to understand age-
related changes in drug effects (Germovsek et al. 2019). Measures of response 
are not always straightforward and can be more difficult to quantify in children. 
Variability in PD response may be even greater than that in PK. There is no 
precise boundary between PK and PD, and exploring the concentration-related 
effects often requires a link describing the movement of a drug from plasma to 
the target tissue and receptors. It is postulated that PD factors such as the number, 
affinity and type of receptors or the availability of natural ligands alter the drug–
receptor interaction and are altered in childhood, but there are few data 
concerning PD differences between adults and children (Anderson et al. 2006). 
There is some evidence from experimental data that the PD effects of inotropes, 
the relationship between drug concentration and the extent of specific response 
vary at different ages (Akita et al. 1994; Artman et al. 1988; Felder et al. 1983; 
Vapaavouri et al. 1973). 
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2.5 Pharmacokinetics of studied inotropes in children and 
neonates 
2.5.1 Pharmacokinetics of dobutamine in children and neonates 
Studies describing the PK of dobutamine in the paediatric population date from 
the 1990s and have been conducted on small numbers of patients of various ages. 
Except for Banner et al., data from those studies indicate that the dobutamine PK 
in the neonatal and paediatric patient population follows first-order elimination 
kinetics within the dose range of 2.5 to 10 μg/kg/min for neonates and 2.5 to 
17.5 μg/kg/min for infants and children. The plasma clearance rate varies widely 
between subjects in paediatric studies, with values ranging from 12.5 to 
1319 ml/kg/min (Banner et al. 1991; Berg, Padbury et al. 1993; Berg, Donner-
stein et al. 1993; Berg et al. 1997; Habib et al. 1992; Martinez et al. 1992; Schwartz 
et al. 1991). The only study describing the PK of dobutamine in neonates has 
reported a mean (standard deviation: SD) plasma clearance of 90 (38) ml/min/kg 
with variability independent of GA and BW. Plasma dobutamine levels correlated 
relatively well with infusion rates, indicating linear clearance in the dose range 
of 2.5–7.5 μg/kg/min (Martinez et al. 1992). The overview of PK studies of 
dobutamine in the paediatric population is presented in Table 1. Only one study 
has reported the volume of distribution with extremely high interindividual 
variability (Schwartz et al. 1991). Similarly, clearance appears to vary largely in 
study populations covering wide age ranges. 
Dobutamine is metabolised through plasma catechol-O-methyltransferase, 
like other catecholamines, and is eliminated predominantly renally. About 80% 
of dobutamine administered intravenously at a steady state to a child with heart 
failure was detected in the urine, largely as 3-O-methyldobutamine-related 
derivatives (47%) and dobutamine metabolites (32%). Sulphate conjugates of 
both 3-O-methyl-dobutamine and dobutamine predominated, comprising 33 and 
16% of the infused dobutamine (Yan et al. 2002). Sulphoconjugation and renal 
excretion are important determinants of the wide interpatient variability in plasma 
free dobutamine clearance rates (Berg et al. 1997). 
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2.5.2 Pharmacokinetics of milrinone in children and neonates 
The PK of milrinone is well described in the perioperative period of open heart 
surgery (OHS); there are studies involving adults, paediatric populations, neo-
nates with hypoplastic left heart syndrome, and children, infants and neonates 
with acute kidney injury (Bailey et al. 1994, 1999, 2004; Gist et al. 2015; Mizuno 
et al. 2019; Ramamoorthy et al. 1998; Zuppa et al. 2006). There are also PK 
studies in paediatric patients with septic shock, neonates with PPHN and very 
preterm infants on the first day of life (Lindsay et al. 1998; Mc Namara et al. 
2013; Paradisis et al. 2007). 
Early studies in healthy subjects confirmed that milrinone is predominantly 
eliminated by renal excretion, with approximately 80% excreted unchanged. The 
renal clearance of milrinone was calculated to be approximately 10 times higher 
than the expected renal clearance by filtration of the unbound drug, clearly indic-
ating that renal secretion is a major contributor to milrinone renal excretion 
(Stroshane et al. 1984). The exact renal secretion pathway has not been invest-
igated. 
An overview of milrinone PK studies in paediatric populations is presented in 
Table 2. Different model standardisation, parameterisation and presentation of 
the clearance values in different units makes it difficult to compare the results of 
these studies.  
Allometric scaling of milrinone clearance to body weight with a power coef-
ficient of 0.75 is described in three studies and maturation as a Emax function of 
PMA with PMA50 estimated as 46.9 weeks in one study (Gist et al. 2015; Mizuno 
et al. 2019; Paradisis et al. 2007). 
A physiology-based PK drug-disease model for milrinone in paediatric 
patients with and without low CO syndrome after OHS highlights that age, disease 
and surgery influence the PK of milrinone, and it proposes optimised dosing 
strategies to ensure safe and effective prescribing to maintain the therapeutic 
target range across the entire paediatric age range (Vogt 2014).
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2.6 Pharmacodynamics of studied inotropes  
in children and neonates 
2.6.1 Monitoring and targets of inotropic treatment 
While aiming for population PKPD modelling of inotropic drugs, a key issue is 
to define proper methods for assessing systemic blood flow and organ perfusion 
in response to the drug under investigation.  
For central HD monitoring in preterm infants, heart ultrasonography is the 
method of choice, although high inter- and intra-observer variability have been 
highlighted as potential problems (Mahoney et al. 2018). The term “functional 
echocardiography” was introduced by Kluckow et al. to describe the bedside use 
of echocardiography to longitudinally assess myocardial function, systemic and 
pulmonary blood flow, and intracardiac and extra-cardiac shunts (Kluckow et al. 
2007). SVCF represents upper body blood flow unaffected by intra- and extra-
cardiac shunts, and low SVCF has been shown to be associated with intra-
ventricular haemorrhage (IVH), adverse neurodevelopmental outcomes, and 
death in premature infants (Hunt et al. 2004; Kluckow et al. 2000; Osborn et al. 
2007, 2003). The effect of repeated neonatal echocardiography on HR, arterial 
oxygen saturation (SaO2), cerebral regional oxygen saturation (rScO2) and 
cerebral fractional tissue oxygen extraction (cFTOE) in extremely preterm infants 
during the first 3 postnatal days has been found to be minimal, and consequently, 
echocardiography is considered to be well tolerated during the postnatal 
transitional period (Noori et al. 2014). 
More recently, NICOM has been used as a hemodynamic assessment tool in 
neonates. Electrical cardiometry is an impedance-based monitor that measures 
the electrical current produced by electrodes and changes in thoracic electrical 
bioimpedance, which is most closely related to thoracic aortic flow and red blood 
cells (RBC) alignment. When aortic flow stops, RBCs in the aorta are randomly 
orientated and impede conduction. Once the LV contracts, the ejection flow 
would compel the RBC to go parallel with the flow, which results in higher con-
ductivity and decreased bioimpedance. The magnitude and frequency of pulsatile 
bioimpedance changes are used to calculate varied hemodynamic measures 
(Osypka et al. 2012). This method has been compared with echocardiography, 
demonstrating a consistent systematic bias in unstable, extremely preterm infants 
with PDA. NICOM may be used as a trending tool for continuous monitoring in 
this population, but it is not interchangeable with echocardiography (Hsu et al. 
2017; Lien et al. 2015; Smits et al. 2017; Weisz et al. 2014). 
Central blood flow measurements do not always correlate well with organ- 
and peripheral perfusion, and restoration of global HD does not always mean that 
adequate tissue perfusion is achieved, especially in conditions of impaired 
autoregulation, as may occur in premature neonates. Measurement of regional 
and microcirculatory blood flow can be used as an indicator of the success of the 
cardiovascular system to provide adequate oxygen and nutrients to the tissues 
(Weil et al. 2007).  
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NIRS was introduced by Jöbsis in 1977 as a safe and non-invasive technique 
to monitor cerebral oxygenation and HD in humans (Jöbsis 1977). It was first 
applied in neonates in 1985 by Brazy et al. (Brazy et al. 1985). The technique is 
based on the transparency of biological tissue to light in the near infrared part of 
the spectrum (700–1000 nm) and its subsequent absorption by chromophores 
present in oxygenated haemoglobin and deoxygenated haemoglobin in the 
cerebral blood vessels at different wavelengths. Current monitoring devices 
incorporate an absolute measure of rScO2 or the cerebral tissue oxygenation index 
(Tisdall et al. 2009). To investigate the balance between oxygen delivery and 
oxygen consumption, the relative cFTOE can be formulated as a ratio: (SaO2-
rScO2)/SaO2, where SaO2 stands for arterial oxygen saturation. An increase of 
cFTOE may indicate reduced oxygen delivery to the brain with constant oxygen 
consumption or brain oxygen consumption that exceeds oxygen delivery. A 
decrease of cFTOE suggests a decrease of oxygen extraction of the brain or 
constant oxygen consumption with increased oxygen delivery (Naulaers et al. 
2007). GA-specific reference curves for rScO2 and cFTOE are provided for the 
first 72 hours of life in preterm infants (Alderliesten et al. 2016). 
Microcirculation plays a crucial role in the interaction between blood and 
tissue, both in physiological and pathophysiological states. It has been shown that 
a haemodynamically significant PDA causes major changes in the micro-
circulation of premature neonates (Hiedl et al. 2010), and in premature neonates 
with sepsis, microcirculatory alterations were already observed in the skin one 
day before changes in laboratory parameters were detectable (Weidlich et al. 
2009). Analysis of these alterations may provide a unique perspective on disease 
processes at the microscopic level (Fagrell et al. 1997). 
Orthogonal polarization spectral (OPS) and side stream dark field (SDF) 
imaging are the first imaging techniques that allow bedside visualization of 
microcirculation using hand-held imaging device. OPS imaging is based on the 
optical technique introduced by Slaaf et al., in which green polarized light is used 
to illuminate the tissue area of interest, which at the bedside is usually the buccal 
or sublingual mucosa (Slaaf et al. 1987). The green light is absorbed by haemo-
globin within the RBC in the microcirculation. The reflected light is detected by 
an orthogonally placed analyser, which filters out surface reflections in order to 
produce a high-contrast reflected light image of flowing RBC within the micro-
circulation (Groner et al. 1999). SDF imaging is the improved successor to OPS 
imaging based on the dark field illumination technique introduced by Sherman et 
al. (Goedhart et al. 2007; Sherman et al. 1971). In this technique, the micro-
circulation can be observed without the need to use trans-illumination. Instead, 
SDF imaging uses a stroboscopic light-emitting diode ring-based imaging device, 
thus providing better image quality of the microcirculation (Balestra et al. 2010). 
OPS and SDF imaging have been validated in several studies. Quantification 
of images is standardized, reproducible and validated (De Backer et al. 2007; 
Boerma et al. 2005). OPS and SDF imaging of the skin have been used in 
premature and term infants (Genzel-Boroviczény et al. 2002, 2004; Hiedl et al. 
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2010; Weidlich et al. 2009). These observations show that microcirculation in 
premature infants can be quantified and RBC velocity can be measured. 
Drugs acting on the cardiovascular system display relatively fast clinical 
responses in the different levels of circulatory system. Complex multimodal 
continuous or easily repeatable bed-side monitoring is needed to get a good 
evaluation of the PD effects of inotropes. However, we have to be aware that 
parameters measured by monitoring tools reflect the sum of multiple actions 
within the same timeframe, and extraction of the drug-specific PD effects from 
these measurements is currently not yet feasible (Smits et al. 2017). Another 
important issue is to find reasonable relationships between these immediate HD 
effects and long-term outcomes. 
 
 
2.6.2 Pharmacodynamics of dobutamine in children and neonates 
Because dobutamine contains an asymmetric carbon atom, there are two 
enantiomers of the drug. The available preparation is a 1:1 racemic mixture of 
the (–)- and (+)-enantiomers. However, the AR affinity of the two optical isomers 
differs substantially. The (–)-dobutamine is a highly selective α1-AR agonist, and 
the (+)-dobutamine exerts a potent and selective β1- and β2-AR stimulatory effect. 
In addition, (+)-3-O-methyldobutamine, the (+) optical isomer of the major 
dobutamine metabolite, is a relatively potent and highly selective α1-AR blocker. 
Thus, the interaction of the two dobutamine enantiomers and (+)-3-O-methyl-
dobutamine with the ARs and receptor expression/developmental pattern 
determine the cardiovascular response to dobutamine (Bhatt-Mehta et al. 1989). 
In adults, cardiac contractility, stroke volume and CO increase with little effect 
on BP. In infants and young children, dobutamine has a significant chronotropic 
effect, which may limit the inotropic response. In general, when studied in infants 
and children, the improvement in CO is in excess of the impact on HR. Improve-
ment in CO fosters improved renal function and urine output in conjunction with 
the resulting relaxation of sympathetic tone. Dobutamine also has modest vaso-
dilator effects in the pulmonary vascular bed (Notterman 1988; Steinberg et al. 
1994). 
The response of the immature cardiovascular system of neonates to dobutamine 
may differ from that of older children and adults (Martinez et al. 1992). Neonates 
with myocardial dysfunction respond favourably to dobutamine, as evidenced by 
increased CO minutes after the initiation of the drug infusion, followed by increases 
in organ blood flow hours later (Robel-Tillig et al. 2007). The cardiovascular 
effects of dobutamine are dose-dependent. A dose escalation study in neonates 
with cardiovascular compromise showed a non-linear threshold effect. At very 
low doses (2.5 μg/kg/min), no significant hemodynamic effects were observed, 
whereas moderate doses (5–7.5 μg/kg/min) increased CO (Martinez et al. 1992). 
Whether these thresholds are physiologically important or related to a particular 
patient population is not yet clear. At doses of 5–20 μg/kg/min, dobutamine has 
been found to increase CO and BP even in hypotensive preterm infants (Roze et 
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al. 1993). Dobutamine at doses of 10 or 20 μg/kg/min was found to be more 
effective than the same doses of dopamine for increasing low SVC flow in 
preterm infants during the first postnatal day (Osborn et al. 2002). 
In a foetal sheep hypoxia-induced brain injury model, dobutamine pre-treatment 
decreased neuroinflammation in the white matter and caudate and did not 
exacerbate cerebral injury or inflammation in the sham group. Early administration 
of dobutamine in preterm infants has been found to be relatively safe and may 
even be neuroprotective (Brew et al. 2018). In a study assessing long-term neuro-
developmental outcomes in preterm babies with low systemic blood flow on the 
first day of life, dobutamine was found to be associated with greater increases in 
systemic blood flow and reduced rates of late severe periventricular or IVH 
compared with infants receiving dopamine (Osborn et al. 2007). In a recent 
randomised placebo-controlled study of 28 preterm neonates (<31 weeks of GA) 
developing circulatory impairment (SVCF <41 ml/kg/min) within the first 12 
hours of life, earlier achievement of normal SVCF in patients receiving 
dobutamine did not reach statistical significance (Bravo et al. 2015). 
 
 
2.6.3 Pharmacodynamics of milrinone in children and neonates 
Experimental data suggest low activity of PDE III in extreme prematurity (Akita 
et al. 1994; Artman et al. 1988). However, no data are currently available on the 
postnatal maturation of the PDE system in humans. 
Few studies in children and neonates after cardiac surgery or in septic shock 
have shown that milrinone also significantly improves cardiac function in this 
population (Bailey et al. 1999; Barton et al. 1996; Chang et al. 1995; Hoffman et 
al. 2003; Lindsay et al. 1998; Ramamoorthy et al. 1998). In very preterm infants, 
milrinone did not prevent low systemic blood flow during the first 24 hours of 
life (Paradisis et al. 2009).  
The PD profile of milrinone has been described in 11 neonates with PPHN: 
milrinone led to an improvement in arterial partial pressure of oxygen and a 
reduction in the fraction of inspired oxygen, oxygenation index, mean airway 
pressure, and inhaled nitric oxide dose, transient reduction in systolic arterial 
pressure following the bolus, improvement in base deficit and plasma lactate, 
lower pulmonary artery pressure, improved RVO and LVO, and reduced 
bidirectional or right-left shunting (Mc Namara et al. 2013). 
The concentration-related effect of milrinone has been described in 11 adult 
patients who had cardiac indices less than 2.5 l/min/m2 immediately after separa-
tion from cardiopulmonary bypass. The relationship between the percentage 
increase in the cardiac index and milrinone plasma concentration was described 
with sigmoidal function, with the fastest change around a concentration of 167 
ng/ml (Bailey et al. 1994). The plasma concentration of milrinone with the fastest 
increase in the velocity of circumferential fibre shortening corrected for HR 
(measurement of LV function) was around 139 ng/ml based on sigmoidal Emax 
dose-response curve (Kikura et al. 1997). 
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In a PK study in a population of infants and children, 50 and 25 μg/kg boluses 
followed by infusion of 0.75 μg/kg/min resulted in a steady state plasma 
concentration (Css) of 206 ± 74 μg/l (Ramamoorthy et al. 1998). In a randomized 
double-blind study comparing milrinone to a placebo in a similar population, a 
comparable milrinone dosage (bolus of 75 μg/kg followed by 0.75 μg/kg/min 
infusion) led to a 55% relative risk reduction for low CO syndrome (Hoffman et 
al. 2003). 
Based on the above data, target concentration ranges of 180–300 ng/ml and 
100–300 ng/ml have also been suggested in paediatric and neonatal populations 
(Gist et al. 2015; Mizuno et al. 2019; Paradisis et al. 2007; Vogt 2014). 
EL-Khuffash et al. have demonstrated that administration of milrinone to 
patients with low LVO (<200 ml/kg/min) 1 hour after PDA surgical closure 
recovered LV performance to levels comparable with the high-LVO group within 
18 hours. Milrinone was administered in 0.33 μg/kg/min intravenous infusion, 
and plasma concentrations were not measured (El-Khuffash et al. 2014). 
Potential adverse effects of milrinone are hypotension, tachyarrhythmias and 
thrombocytopenia (Ramamoorthy et al. 1998; Stroshane et al. 1984). Although 
often reported in adult patients, they are infrequent in paediatric patients and are 
probably not always caused by milrinone (Hoffman et al. 2003). 
 
 
2.7 Summary of the literature 
Inotropic therapy in neonates is mainly based on knowledge of the patho-
physiology behind the cardiovascular dysfunctional status and the PK and PD 
properties of the medications based on adult data. There is limited evidence about 
short-term effects of dobutamine and milrinone in critically ill neonates (Bravo 
et al. 2015; El-Khuffash et al. 2014; Martinez et al. 1992; Paradisis et al. 2009). 
However, the dose-concentration-response relationships remain poorly under-
stood. The long-term neurodevelopmental effects of inotropic therapies used 
during critical illness of neonates has remained unestablished.  
If not appropriately dosed, these medications may induce abrupt, excessive, 
and potentially harmful fluctuations in BP and systemic and organ blood flow 
(Greisen 2008; O’Leary et al. 2009; du Plessis 2009; Seri et al. 1993). Thus, in 
addition to cardiovascular compromise, treatment by suboptimal administration 
of inotropes, lusitropes, and vasopressors may contribute to short- and long-term 
morbidities in critically ill preterm and term neonates (Barrington 2008; O’Leary 
et al. 2009; du Plessis 2009). 
Prompt diagnosis of neonatal cardiovascular compromise by state-of-the-art 
hemodynamic monitoring of BP and systemic and organ blood flow and careful 
titration of the vasoactive agents to the optimal hemodynamic response are 
thought to be of importance in decreasing mortality and morbidity associated with 
shock in preterm and term neonates (Goldstein et al. 1995; Martens et al. 2003; 
Seri 2001; Seri et al. 1993; Soleymani et al. 2010). 
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For milrinone, there is data about the PK properties in different specific patient 
populations, but pooling the information together, extrapolating between different 
populations and implementing conclusions into clinical practice has remained 
difficult. For dobutamine, existing PKPD information dates largely from the early 
1990s. No studies have described dose-concentration-effect relationships through 
methods of non-linear mixed effects modelling. 
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3. AIMS OF THE RESEARCH 
The general aim of the thesis was to describe the population pharmacokinetics 
and pharmacodynamics of two cardiovascular drugs, dobutamine and milrinone, 
in two clinical situations in which these medications are often used – post-ligation 
cardiac syndrome prevention after surgical closure of patent ductus arteriosus 
and transitional circulation of critically ill neonates. 
 
The specific aims were: 
 
1. To review the existing data on pharmacokinetics of milrinone in preterm 
infants and, by using the in silico probability of target attainment simulations, 
work out the best suitable dosing regimen for subsequent trial on neonates 
undergoing surgical closure of patent ductus arteriosus.  
 
2. To describe the pharmacokinetics of milrinone when used for the prevention 
of post-ligation cardiac syndrome in neonates undergoing ligation of patent 
ductus arteriosus. 
 
3. To develop dosing recommendations for milrinone in this patient group, based 
on prospectively collected pharmacokinetic data. 
 
4. To describe the pharmacokinetics of dobutamine during the transitional 
circulation period in neonates, i.e. during their first three days of life 
 
5. To describe the concentration-effect relationship of dobutamine on central and 
regional cerebral hemodynamic responses in neonates during the transitional 
circulation period. 
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4.PATIENTS AND METHODS 
The thesis is based on one in silico simulation study using demographic data of a 
retrospective patient population and two prospective clinical trials conducted in 
NICUs of Tallinn Children’s Hospital and Tartu University Hospital. The details 
of the study design are summoned in Table 3. Study-specific details of the patient 
population selection and data analysis will be outlined separately below for each 
study.  
 
Table 3. Description of the studies 
Study/Design Timing Population Aim Publication 
Milrinone 
simulation study 
In silico 
simulations 
Retrospective 
population from 
January 2012 – 
December 2014
31 neonates 
undergoing 
PDA surgical 
closure
To propose a 
dosing regimen for 
a prospective PK 
study of milrinone.
I 
Milrinone PK 
study 
Prospective PK 
study using 
nonlinear mixed 
effects modelling 
June 2015 –  
October 2017 
10 neonates 
undergoing 
PDA surgical 
closure and at 
risk of PLCS 
To describe the 
population PK of 
milrinone in 
premature neonates 
at risk of PLCS and 
give dosing 
recommendations.
II 
Dobutamine 
PKPD study 
Prospective 
PKPD study 
using nonlinear 
mixed effects 
modelling 
 
April 2016 – 
December 2017
28 neonates 
within PNA 
of 72 hours 
To describe the PK 
and concentration-
related effects of 
dobutamine in the 
population of 
critically ill 
neonates in the first 
days of life. 
III 
 
 
4.1 Ethical considerations 
The two prospective clinical studies were approved by the Research Ethics 
Committee of the University of Tartu and by the State Agency of Medicines of 
Estonia (EU Clinical Trials Register No. 2015-000486-31 and 2015-004836-36). 
Written informed consent was signed by the parent(s) before inclusion in the 
study. 
To find the best dosing of the studied medications based on already existing 
knowledge, an in silico simulation study preceded the milrinone PK study. As 
anonymized demographic data were available from a prior clinical practice 
review, for this analysis, a separate Ethics Committee approval as well as 
informed consent were not considered necessary. 
37 
Blood samples for PK analysis were obtained from indwelling catheters, and 
the overall sample volume did not exceed 3% of calculated circulating blood 
volume (Committee for Medicinal Products for Human Use (CHMP) et al. 2008). 
A sensitive method was developed and validated for detecting low levels of 
dobutamine and milrinone in a small amount of plasma (Takkis et al. 2019). 
 
 
4.2 Study populations 
4.2.1 Milrinone simulation study population (Study I) 
Demographic characteristics, including GA, BW, weight, and PNA on the day of 
surgery, were collected from the hospital records of a retrospective population. 
The study population consisted of all neonates who underwent PDA ligation in 
the NICUs of the Tartu University Children’s Clinic and Tallinn Children’s 
Hospital between January 2012 and December 2014.  
 
 
4.2.2 Milrinone PK study population (Study II) 
All neonates and infants up to 90 days of age requiring PDA ligation during the 
study period (June 2015 to October 2017) were screened for the PK study.  
Neonates were included if they fulfilled all of the following criteria: (a) were 
up to 90 days of age; (b) had haemodynamically significant PDA requiring surgical 
ligation; (c) had an arterial catheter and/or central venous catheter in place on 
clinical indication and (d) informed consent was signed by the parents or guardians.  
Neonates with any of the following were excluded: (a) renal failure requiring 
renal replacement therapy (peritoneal dialysis) or serum creatinine (SCr) 
>100 μmol/l or oliguria <0.5 ml/kg/min within 6 hours; (b) hypersensitivity to 
milrinone or any other component of the study drug; (c) treating physician 
considered milrinone contraindicated; (d) major congenital malformation; 
(e) known metabolic disease; (f) informed consent from parents or guardians not 
obtained; (g) critically unstable state of the patient, likely to be fatal within 
72 hours; or (h) already recruited in another clinical trial investigating a medical 
product. 
In dose optimisation simulations, PMA and weight data from all PDA ligation 
patients treated in the study units between 2013 and 2017 were used. The 
population included the retrospective population of the milrinone simulation 
study and the prospective milrinone PK study population, including those who 
did not receive milrinone treatment. 
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4.2.3 Dobutamine PKPD study population (Study III) 
All neonates hospitalized to NICU within the first 72 hours of life from April 
2016 to December 2017 were screened for eligibility. We included neonates with: 
(a) PNA below 72 hours; (b) the need for inotropic therapy according to the 
decision of the treating physician (based on echocardiographic assessment, 
rScO2, mean arterial blood pressure (MAP), acid-base balance, serum lactate and 
capillary refill time); (c) an arterial catheter and/or central venous catheter in 
place on clinical indication and (e) parents’ signed informed consent. Neonates 
with the following were excluded: (a) a congenital defect that impacts HD 
response to inotropic therapy (congenital heart disease); (b) congenital hydrops; 
(c) other unresolved cause of low blood flow (air leak); (d) known metabolic 
disease; (e) informed consent not signed by parents or guardians; (f) situation 
where the treating physician considered a different vasoactive treatment necessary/ 
dobutamine contraindicated; or (g) known hypersensitivity to dobutamine or any 
other component of the study drug. 
 
 
4.3 Study drug administration  
4.3.1 Milrinone administration (Study II) 
Milrinone was started in infants determined to be at risk of PLCS based on 
echocardiographic assessment of LVO of less than 200 ml/kg/min 1 hour after 
the end of PDA surgery. Milrinone (Corotrope 1mg/ml, Sanofi-Aventis, France) 
was diluted with 0.9% NaCl to a concentration of 15 μg/ml within 20 min before 
administration. A loading dose of 0.73 μg/kg/min over 3 hours was followed by 
a maintenance infusion of 0.16 μg/kg/min for 21 hours, based on the milrinone 
simulation study results, as shown in Figure 1. 
To ensure adequate intravascular volume, all infants received a bolus of 
9 ml/kg of normal saline over three hours with the milrinone loading dose 
infusion. Further hemodynamic support with fluid boluses and inotropes was 
provided according to the routines of the unit. The milrinone infusion rate could 
be changed or discontinued at the discretion of the treating physician. 
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Figure 1. Milrinone PK study time-flow: LVO – left ventricular output, PDA – patent 
ductus arteriosus, PK – pharmacokinetic, vital signs (heart rate, blood pressure, peripheral 
arterial oxygen saturation, cerebral regional oxygen saturation) were continuously 
recorded from patient monitors. 
 
 
4.3.2 Dobutamine administration (Study III) 
Infusion of the studied medication was started immediately after the first echo-
cardiographic assessment. Dobutamine in a 12.5 mg/ml concentrate for solution 
for infusion (Dobutamine Claris, Claris Lifesciences (UK) Limited, UK) was 
diluted with 0.9% NaCl to a concentration of 1.25 mg/ml within 20 min before 
administration. 
Treatment was started at a dose of 5 μg/kg/min and raised by 5 μg/kg/min 
approximately every 30 min to a maximum of 20 μg/kg/min, as shown in Figure 2. 
Dose change times were recorded with the precision of the nearest minute.  
The individual dose escalation maximum was decided based on echo-
cardiographic and clinical findings. Dose-limiting effects of the study medication 
were (1) persistent tachycardia (HR >200 min–1 in preterm and >180 min–1 in 
term neonates) or arrhythmias, (2) no additional effect from the last dose increase 
or (3) sufficient effect of the last dose. To ensure adequate intravascular volume, 
all neonates received a bolus of 10 ml/kg of 0.9% NaCl over 10 min, unless any 
fluid bolus was already received within 4 hours prior to study inclusion. 
Concomitant treatment with volume bolus and inotropes other than the study 
medication was provided on the decision of the treating physician without any 
restrictions in the study protocol.  
 
1 2 3 4
0.73 0.16
Echocardiography: LVO
Recordings from patient monitors
Milrinone dosing (μg/kg/min)
PK sampling
Time
0 3h 24h
PDA ligation operation
28h 36h-2h -1h
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Figure 2. Dobutamine PKPD study time-flow: RVO – right ventricular output, LVO – 
left ventricular output, LVEF – left ventricular ejection fraction, HR – heart rate, MAP – 
mean arterial blood pressure, SaO2 – peripheral arterial oxygen saturation, rSO2 – cerebral 
regional oxygen saturation, PK – pharmacokinetic. PK sampling 15–30 min after every 
dose change and 15 min after completion of therapy. Recordings from patient monitors 
were made continuously. 
 
 
4.4 Pharmacokinetic sampling 
For the concentration measurement of the studied drugs, blood samples of 0.3 ml 
were collected from an indwelling arterial line into Na-heparin vials. Actual 
blood collection time was recorded with the precision of the nearest minute. The 
samples were centrifuged immediately (10 min at 3500 rpm), plasma separated 
and stored at –80 °C (up to 12 h storage at –20 °C prior to transfer to –80 °C was 
accepted) and transported on dry ice for analysis. Study-specific sampling times 
are outlined in Figures 1 and 2. 
 
 
4.4.1 Milrinone PK study pharmacokinetic sampling (Study II) 
Blood samples for milrinone plasma concentration measurements were collected 
at the end of loading infusion (3h), at the end of maintenance infusion (24 h) and 
twice after the end of treatment (28 h, 36 h), as shown in Figure 1. 
 
 
4.4.2 Dobutamine PKPD study pharmacokinetic sampling (Study III) 
Blood samples for dobutamine plasma concentration measurements were collected 
15–30 min after every dobutamine dose change and 15 min after termination of 
dobutamine infusion, as shown in Figure 2. A maximum of six blood samples 
were drawn from one subject.  
1 2 3 4 5
5 10 15 20 x
Echocardiography: RVO, LVO, LVEF
Recordings from patient monitors:
HR, MAP, SaO2, rSO2
Dobutamine dosing (μg/kg/min)
PK sampling
Time
0 0.5 h 1h 1.5 h 2 h
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4.5 Drug concentration measurements 
A method to obtain the plasma concentration measurements for the studied 
medications was developed and validated by Karin Kipper, Kalev Takkis and 
Rūta Veigure, and all the plasma samples were analysed at the Institute of 
Chemistry, University of Tartu. 
Milrinone and dobutamine concentrations were measured by ultra-high-per-
formance liquid chromatography coupled with tandem mass spectrometry 
(UHPLC-MS/MS). A sensitive method for both investigated medications with 
the quantification range of 1–300 μg/l and sample volume of 20 μl was developed 
(Takkis et al. 2019). 
The problem of extreme instability of dobutamine in plasma samples was 
overcome by adding a stabilising agent (ascorbic acid) to the plasma during the 
thawing phase. Extensive stability testing was undertaken to ensure the validity 
of the results. 
The within- and between-run accuracy (coefficient of variability) for milrinone 
was 97–106% (3–7%) and 97–106% (3–9%), respectively; for dobutamine 95–
99% (4–7%) and 94–102% (3–5%), respectively. The lower limit of quanti-
fication (LLOQ) was determined as 0.97 ng/ml for both analytes. 
All plasma concentrations detected below the LLOQ were included in the 
analysis with the value of 0.5 μg/l (half the LLOQ); this was the case only in 
dobutamine study (Study III). 
 
 
4.6 Haemodynamic data collection and safety monitoring 
All studied neonates and infants were treated in a Level 3 NICU and monitored 
according to routine clinical practice. During the treatment period with the study 
medications, HR, arterial BP, SaO2 and other vital signs were continuously 
monitored with IntelliVue MP30, M70 or MX800 patient monitors (Philips 
Medical Systems, The Netherlands), cerebral regional saturation with NIRS 
monitor Invos Oxymeter (Medtronic, USA) and recorded with 2.5 s intervals by 
BedBase software (University Medical Center Utrecht, the Netherlands).  
Cardiac function and central blood flows were measured using echocardio-
graphy by cardiologists. Studies were performed using the Vivid 7 Dimension or 
Vivid E9 cardiovascular ultrasound system (GE Healthcare, USA) with 10 or 
12 MHz transducers, respectively. Evaluations included measurements of RVO 
and LVO, SVCF and shunting trough PDA and foramen ovale (when applicable), 
systolic function of left and right ventricle and diastolic function of the heart 
(Evans et al. 1996; Kluckow 2000). Study-specific timing of measurements is 
shown on Figure 1 and Figure 2. 
The PD effect measures of RVO, LVO, SVCF and left ventricular ejection 
fraction (LVEF) were recorded before the dosing and once at each infusion rate 
of dobutamine, approximately 20–30 min after each dose escalation; HR, MAP, 
SaO2 and rScO2 data recorded during a 15 min period (5 min before and 10 min 
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after each dose change) were selected, artefacts removed manually and averaged 
over 1 min, and cFTOE was calculated as the ratio: (SaO2-rScO2)/SaO2. 
All neonates were monitored for adverse events for 7 days after the end of 
treatment with a study medication. Monitoring included clinical evaluation, 
cerebral ultrasonography, laboratory and vital parameters and administration of 
concomitant medications. 
 
 
4.7 Pharmacokinetic and pharmacodynamic modelling 
PKPD modelling was undertaken with nonlinear mixed-effects software 
NONMEM version 7.3 (ICON Development Solutions, MD, USA). The first-
order conditional estimation method with interaction was used. The selection of 
the population model and residual error model was based on goodness-of-fit 
(GOF) plots and an improvement in the objective function value (OFV). For a 
nested model, a parameter was added if their inclusion resulted in improvement 
of OFV value >3.84 (P < 0.05 by likelihood ratio test for 1 degree of freedom). 
Between subject variability (BSV) of the model parameters was described 
using an exponential error model (Equation 6), which assumes parameters are 
log-normally distributed:  
 
 𝑝 = 𝜃 ∙ exp (𝜂 ) Equation 6 
 
where pi refers to the individual value of the respective PK or PD parameter in 
the i-th individual, θ is the typical parameter value, and exp(ηi) expresses the 
random difference between θ and pi. 
For describing and quantifying residual unexplained variability, an additive 
(Equation 7), proportional (Equation 8) and a combination of the two (Equation 9) 
were tested: 
 
 𝑌 = 𝐶 + 𝜀  Equation 7 
 
 𝑌 = 𝐶 ∙ 1 + 𝜀  Equation 8 
 
 𝑌 = 𝐶 ∙ 1 + 𝜀  + 𝜀   Equation 9 
 
where Cij is the j-th drug plasma concentration or PD effect of the i-th individual 
predicted by the PK or PD model, and Yij is the measured plasma concentration 
or effect. The residual departure of Yij from Cij is represented by εij. 
To assess the GOF of the models, population and individual predicted vs. 
observed dobutamine Cp and PD effect measurements, absolute value of individual 
weighted residuals versus individual predictions, and conditional weighted 
residual error versus time plots were constructed with R software using package 
xpose4 (Jonsson et al. 1999; R Core Team 2014a). 
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4.7.1 Milrinone simulation study analysis (Study I) 
Published milrinone population PK studies were reviewed for the characteristics 
of the study population and intervention.  
We created 1,000 individual PK parameter value sets by simulating the chosen 
PK model with bootstrapped collected demographic data from our retrospective 
study population. Individual PK estimates were used in simulating time-con-
centration profiles with varied loading and maintenance doses.  
First, the concentration-time profile of milrinone was simulated with a 
continuous infusion of 0.3 μg/kg/min, a dose proposed by a previous study of 
PLCS prevention (Jain et al. 2012). According to the timely course of PLCS, a  
3-hour loading dose with maintenance infusion until 24 hours was chosen for 
dose optimisation simulations.  
The concentration target was chosen based on data from previous PKPD studies 
of milrinone in paediatric and neonatal patients undergoing OHS (Ramamoorthy 
et al. 1998; Zuppa et al. 2006). In a PK study by Ramamoorthy et al., 50 and 
25 μg/kg boluses followed by infusion of 0.75 μg/kg/min resulted in a steady state 
plasma concentration of 206 ± 74 μg /l (Ramamoorthy et al. 1998). In a ran-
domized double-blind study in a similar population that compared milrinone to a 
placebo, a milrinone bolus of 75 μg/kg followed by 0.75 μg/kg/min infusion led 
to a 55% relative risk reduction for low cardiac output syndrome (Hoffman et al. 
2003). Based on these data, a milrinone concentration of around 200 μg /l was 
considered effective in the prevention of low cardiac output. Bearing in mind the 
preventive character of intervention and the presumed lower volume of distri-
bution in our study population compared to the PK model population of preterm 
neonates aged 1–2 days, a more conservative upper limit of target concentration 
was chosen to avoid overdosing. The two former studies addressing optimal 
dosing of milrinone in preterm and term neonates targeted concentrations of 180–
300 and 100–300 μg /l, respectively (Paradisis et al. 2007; Vogt 2014). In our 
study, maximising the number of simulated subjects in the concentration range 
of 150–200 ng/ml for at least 80% of time in the maintenance phase was targeted.  
All simulations were conducted by Tõnis Tasa (Institute of Computer Science, 
University of Tartu) using R software version 3.0 (R Core Team 2014b). 
 
 
4.7.2 Milrinone PK study analysis (Study II) 
One- (Equation 10) and two-compartment linear structural models (Equation 11) 
were considered to describe the PK of milrinone: 
 
 ∆∆ = 𝑅𝑎𝑡𝑒 − ∙  Equation 10 
 
where rate represents the infusion of the drug, A is the amount of the drug in the 
body, CL is first-order elimination clearance, and V is the volume of distribution;  
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∆𝐴∆𝑡 = 𝑅𝑎𝑡𝑒 − 𝐶𝐿 ∙ 𝐴𝑉 − 𝑘 ∙ 𝐴 + 𝑘 ∙ 𝐴  
 
 ∆∆ =  𝑘 ∙ 𝐴 − 𝑘 ∙ 𝐴  Equation 11 
 
where Ac and Ap are the amounts of drug in the central and peripheral compart-
ments, respectively. CL is the first-order elimination clearance, and Vc is the 
volume of the central compartment, and kcp and kpc are the first order intercom-
partmental rate constants.  
Body weight and PMA were included a priori in the model with allometric 
weight scaling and a function describing GFR maturation, respectively 
(Equation 1 and Equation 2) (Germovsek et al. 2017). The power coefficient of 
clearance and parameters of the maturation function were fixed to values from a 
previous study of human glomerular filtration development (Equation 12 and 
Equation 13) (Rhodin et al. 2009) 
 
 𝐶𝐿 = 𝜃 ∙ . ∙ .. . .  Equation 12 
 
 𝑉 =  𝜃 ∙  Equation 13 
 
where CLi and Vi are the individual predicted values for clearance; V, θCL and θV 
are the typical values of clearance; V, WD1i is the patient’s weight on day one of 
the study; Wst is the population mean bodyweight; and PMAi is the patient’s PMA 
on day one of the study. 
Other patient covariates (such as sex, Apgar score, albumin level, fluid intake, 
CO and co-administration with dopamine or dobutamine) were tested for 
correlation with model parameters. 
A nonparametric bootstrap with 2000 replicates was undertaken to assess the 
robustness of parameter estimates to changes in data, and a visual predictive 
check (VPC) was performed to assess the simulation properties of the final 
model, using the software Perl speaks NONMEM and R Version 3.3.3 (Lindbom 
et al. 2005; R Core Team 2014a). 
Probability of target attainment (PTA) simulations aimed to develop a dosing 
schedule that maximally attains milrinone concentration within the pre-specified 
target range of 150–250 μg/l by the 6th postoperative hour for the majority of 
patients. Compared to the milrinone simulation study, the upper limit of target 
concentration was raised based on the safety profile seen in the prospective 
milrinone PK study. Severe hypotension with additional vasopressor treatment 
was recorded only in two infants with milrinone plasma concentrations exceeding 
300 μg/l. Patient covariate (PMA and weight) data were bootstrapped to 1,000 
samples. Next, patient PK parameters were simulated using parameter equations 
and variability estimates from the PK model. Milrinone time-concentration 
curves were simulated with doses ranging from 0 to 1 μg/kg/min, with a step of 
0.05 μg/kg/min. The dosing scheme consisted of a 3-hour loading dose 
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immediately followed by a 21-hour maintenance infusion, as explained by the 
time course of PLCS, also in Study I. 
First, an optimal loading dose with a precision of 0.05 μg/kg/min was 
identified, maximising the PTA within the concentration target range of 150–
250 μg/l at three hours after start of the initial infusion, and the result was used 
as a pre-condition for maintenance dose optimization. The optimal maintenance 
dose achieved a maximum of mean PTA values measured at 6, 12, 18 and 
24 hours of treatment. The probability of concentrations above 300 μg/l was 
taken into account to minimize potential side effects from excessive concen-
trations. Specifically, dose optimisation of maintenance and loading dose 
maximised the objective function (Equation 14): 
 
 Equation 14 
 
where Target1i is the proportion of simulated concentrations within 150–250 μg/l 
range at the i-th observation time and Target2i is the same for concentrations 
above 300 μg/l with maintenance dose x starting at the end of the loading phase 
(3 hours after start). Weight constant w is fixed at 1. 
Additionally, to consider dose requirement changes related to PMA, we aimed 
to find a PMA breakpoint that divides the population into two patient subgroups 
with different unknown maintenance doses. The optimization found a 
combination of parameters that provided maximal PTA and used the following 
optimization function (Equation 15): 
 arg max, ∈{ , . ,…, },∈{ , ,…, }  ( (𝑇𝑎𝑟𝑔𝑒𝑡1 (𝑥, 𝑦, 𝑃𝑀𝐴) − 𝑤 ∗ 𝑇𝑎𝑟𝑔𝑒𝑡2 (𝑥, 𝑦, 𝑃𝑀𝐴)))/𝑛 
Equation 15 
 
where Target1i is the proportion of simulated concentrations within 150–250 μg/l 
range at the i-th observation time and Target2i is the same for concentrations 
above 300 μg/l with maintenance dose x (in subjects age < PMA) and y (in 
subjects age ≥ PMA) starting at the end of the loading phase (3 hours after start), 
PMA is the postmenstrual age determining the two different maintenance dose 
groups and w is again set as 1. 
All simulations were conducted by Tõnis Tasa (Institute of Computer Science, 
University of Tartu) using R software Version 3.3.3 (R Core Team 2014a). 
 
 
4.7.3 Dobutamine PKPD study analysis (Study III) 
To describe the PK of dobutamine one-compartmental structural PK models with 
first-order elimination (Equation 10), Michaelis-Menten elimination (Equation 
16) and elimination by parallel first-order and Michaelis-Menten processes 
(Equation 17) were evaluated: 
arg max∈{ , . ,…, }  ( (𝑇𝑎𝑟𝑔𝑒𝑡1 (𝑥) − 𝑤 ∗ 𝑇𝑎𝑟𝑔𝑒𝑡2 (𝑥)))/𝑛 
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∆∆ = 𝑅𝑎𝑡𝑒 − ∙  Equation 16 
 
 
∆∆ = 𝑅𝑎𝑡𝑒 − ∙ − ∙  Equation 17 
 
where A is the amount of dobutamine in the body, CL is first-order elimination 
clearance, V is the volume of distribution; Vmax the maximal rate of Michaelis-
Menten elimination and KM (Michaelis Constant) is the amount of dobutamine 
in the body when the elimination rate by the Michaelis-Menten mechanism is half 
maximal.  
Clearance and volume of distribution were a priori allometrically scaled to 
the population median BW, and a maturation function, describing the maturation 
of dobutamine clearance with PMA, was applied (Equation 18 and Equation 19):  
 
 𝐶𝐿 =  𝜃 ∙ . ∙  Equation 18 
 
 𝑉 = 𝜃 ∙  Equation 19 
 
where CLi and Vi are the individual predicted values for clearance and V, θCL and 
θV typical values for clearance; V, BWi and PMAi are the patient’s individual BW 
and PMA; Wst is the population median BW; Hill is the sigmoidicity coefficient; 
and PMA50 is the PMA when the maturation of the dobutamine clearance reaches 
50% of adult values (Germovsek et al. 2017). PMA50 and Hill’s coefficient for 
the maturation function of dobutamine clearance were estimated from PK data. 
In covariate analysis parameterization of the PK model with PNA, antenatal 
glucocorticoid hormone administration, coadministration of dopamine, blood 
haemoglobin and albumin concentration, PDA diameter, baseline LVEF and 
baseline RVO were tested.  
Using the final linear PK structural model with fixed Hill’s coefficient and 
PMA50 parameter values from the PK model fitting process, simultaneous PKPD 
modelling was undertaken with HD parameters as PD effect.  
Considering that the HR, MAP, SaO2 and rScO2 measurements were recorded 
continuously around the dose change, we attempted to estimate the effect time 
which represents the distribution of the drug from plasma to the effect site at a 
steady state. An effect compartment with a first-order equilibration rate constant 
(keo) was added to the final PK structural model for HR, MAP and cFTOE PKPD 
models, assuming that the amount of drug distributing into the effect 
compartment does not influence the overall PK (Equation 20): 
 
 ∆∆ = 𝑘 ∙ 𝐶 − 𝑘 ∙ 𝐶  Equation 20 
where Cp is the plasma concentration and Ce the effect compartment concen-
tration, and keo is the equilibration rate constant between effect and observed 
(plasma) compartments. 
47 
Baseline HD parameter values were estimated. Changes in HD parameter 
values were explored using linear (Equation 21), Emax (Equation 22) and sig-
moidal Emax (Equation 23) models: 
 
 𝐸 = 𝐸 , + 𝑆𝐿 ∙ 𝐶  Equation 21 
 
 𝐸 = 𝐸 , + 𝐸 , − 𝐸 , ∙ ,  Equation 22 
 
 𝐸 = 𝐸 , + (𝐸 , − 𝐸 , ) ∙ ( , ) Equation 23 
 
where Eij is the j-th observed effect at the corresponding plasma or effect com-
partment concentration (Cij) of the i-th individual, E0,i represents the estimated 
baseline value, SLi is the slope of the linear relationship between Eij and Cp,ij for 
the i-th individual, Emax,i is the estimated maximum HD parameter value for the 
i-th individual, and EC50,i represents the concentration at half-maximal effect for 
the i-th individual. The Hill coefficient (γ) describes the steepness of the 
concentration response relation. 
BSV was estimated for most of the PK and PD model parameters using an 
exponential variance model (Equation 6), assuming log-normal parameter distri-
bution. Individual η-s for clearance and the volume of distribution were highly 
correlated (r =1.0), so a shared η was used with an estimated scale factor applied 
to the shared η for the volume of distribution (Equation 24), 
 
 𝐶𝐿  =   𝐸𝑋𝑃   
 
 𝑉  =   𝐸𝑋𝑃 (  ) Equation 24 
 
where CLi is the individual value of CL, θCL the typical value of CL, ηi the shared 
interindividual variance, Vi the individual value of V, θV the typical value of the 
volume of distribution and θn is the estimated variance scale factor. The residual 
unexplained variability was explored to be described by additive (Equation 7), 
proportional (Equation 8), or combined additive and proportional error models 
(Equation 9). The residual error was estimated separately for the PK and PD 
observations. 
For the final PK model and all PKPD models, prediction corrected VPC was 
constructed and a nonparametric bootstrap with 1,000 replicates was undertaken 
with the software Perl speaks NONMEM and R Version 3.6.0 (Lindbom et al. 
2005; R Core Team 2019). 
Descriptive statistics of the study populations are presented as median (range) 
or mean (range). Echocardiography recordings of 20% of study patients attained 
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by three different cardiologists were reanalysed by one observer for intra- and 
inter-observer variability, according to a recent recommendation (Popović et al. 
2017). 
Sequential measurements of central blood flow and cardiac function were 
analysed using a paired Wilcoxon test with R software Version 3.6.0 to assess the 
overall change in those parameter values (R Core Team 2019). 
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5. RESULTS AND DISCUSSION 
5.1 Milrinone simulation study results (Study I) 
5.1.1 Demographics and PK model selection 
The retrospective population consisted of 31 patients who underwent a PDA 
closure operation during the study period. The median (range) GA was 26 (23–35) 
weeks, PNA 13 (3–29) days, and body weight on the day of surgery 760 (500–
2,351) g. 
We found five paediatric population PK models in the literature. Four of them 
were for populations undergoing OHS and included various age groups and one 
was for preterm neonates within the first 12 hours of life (Bailey et al. 1999, 2004; 
Paradisis et al. 2007; Ramamoorthy et al. 1998; Zuppa et al. 2006). For popu-
lation and PK details of those models, see Table 2, studies 2–6. 
A one-compartmental population PK model by Paradisis for preterm neonates 
was chosen for milrinone plasma concentration simulations as the one with the 
highest resemblance to the target population. Population estimates for clearance 
and the volume of distribution were 35 ml/h and 512 ml, respectively. Between-
subject variability estimates for model parameters were 24 and 21%, respectively 
(Paradisis et al. 2007). 
As body weight was a single covariate affecting both clearance and the volume 
of distribution of milrinone via allometric scaling with a power coefficient of 0.75 
and 1, respectively, only the body weights of the study population were used to 
create the individual PK parameter value sets for dose optimization simulations. 
 
 
5.1.2 Dose finding simulation results 
With a dosage of 0.33 μg/kg/min, at 6 hours of therapy, the simulated plasma 
concentrations lie within the target range of 150–200 μg/l only in 35.9% of 
subjects. After 18 hours of milrinone infusion, simulated plasma concentrations 
remained in the therapeutic range for just 0.8% of subjects, exceeding the 
literature-based recommended/safe window for the rest (Figure 3). 
The plasma concentration target was best achieved with a 3-hour loading 
infusion of 0.73 μg/kg/min followed by a maintenance infusion of 0.16 μg/kg/min 
(Figure 3). The proportion of subjects with simulated milrinone plasma concen-
trations within the target range (150–200 μg/l) was 7% after 2 hr and 32.2% after 
2.5 hr of treatment. At 3 hr of treatment, at the beginning of the maintenance 
dose, 51.2% of subjects had simulated plasma concentrations within the target 
range. This percentage also remained similar after 6, 18, and 24 hr of treatment, 
with 56.1, 58.1, and 55.7%, respectively. 
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Figure 3. Milrinone concentration-time profiles of 1,000 simulated subjects: A with a 
continuous infusion of 0.33 μg/kg/min; B with a 3-hour loading infusion of 0.73 μg/kg/min 
followed by a 21-hour maintenance infusion of 0.16 μg/kg/min. Median estimates are 
presented with blue solid lines, red dashed lines show 90% CI, and the target concen-
tration of 150–250 μg/l and the time period of 6–18 hr after the start of drug adminis-
tration are marked with grey dotted lines. 
 
The long half-life of milrinone in neonates, 10 hours according to Paradisis et al., 
suggested the need for a loading dose to achieve therapeutic concentration within 
a reasonable time, while low clearance refers to possible accumulation of the drug 
when administered continuously (Paradisis et al. 2007). The simulation study 
results confirmed improvement of therapeutic concentration attainment within a 
clinically relevant time frame with loading infusion and a lower maintenance 
dose compared to an unchanged continuous infusion rate.  
We carried the best simulated dosing regimen forward to our next prospective 
milrinone PK study. 
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5.2 Milrinone PK study results (Study II) 
5.2.1 Demographics of the milrinone PK study population 
Altogether, 21 neonates underwent PDA ligation surgery within the study period. 
All operations were performed in NICU by one experienced surgeon and under 
intravenous anaesthesia with ketamine, fentanyl and atracurium. Seven neonates 
were excluded for the following reasons: (1) participation in another clinical 
study (n=3), (2) absent parental consent (n=2) and (3) renal failure with creatinine 
>100 μmol/l (n=2). We recruited 14 patients into the study, of which 10 received 
milrinone according to the study protocol (publication II, Figure 1).  
Low LVO (<200 ml/kg/min) at 1 hour after PDA ligation was measured in 10 
patients, and all of them were treated with milrinone according to the study 
protocol. The population mean (range) PMA and body weight on the day of PDA 
ligation were 27.4 (24.6–30.1) weeks and 857.3 (568.0–1114.0) g, respectively 
(Table 4). 
Dose optimization simulations included PMA and weight data from 52 
patients with mean (range) PMA and bodyweight of 27.6 (23.3–37.3) weeks and 
875.5 (500.0–2351.0) g, respectively. 
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5.2.2 Pharmacokinetics of milrinone 
Forty time-concentration data points, four from each patient, were available for 
PK analysis. The median (range) milrinone plasma concentrations at 3, 24, 28 
and 36 hr were 279.7 (213.6–366.2), 186.7 (84.3–361.0), 105.1 (27.1–227.3) and 
45.4 (3.0–113.3) μg/l, respectively. Individual time-concentration profiles of the 
study patients are presented in Figure4. 
A one-compartmental linear structural model with a proportional residual 
error model adequately described the population PK data. Adding a second 
compartment to the PK structural model did not lower the OFV (292.8 vs. 291.9). 
Adding allometric scaling to body weight and maturation function of GFR of the 
model parameters to the structural model (Equation 12 and Equation13) reduced 
the OFV from 291.9 to 273.1.  
Figure 4. Measured milrinone plasma concentrations. Each colour refers to a patient as 
presented in Table 4. Dashed lines refer to the target concentration range of Study I 
simulations. The patient numbers are in concordance with Table 4. 
 
The final population mean (coefficient of variation) parameter estimates for 
clearance and volume of distribution were 0.350 l/h/857.3g (11.6%) and 0.329 
l/857.3g (32.6%), respectively. Similar PK parameter estimates from the final 
model NONMEM run and bootstrap analysis demonstrate the robustness of the 
model (Table 5). 
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Table 5. Final parameter estimates with uncertainty from the NONMEM output file and 
from bootstrap analysis results. 
 Values from  
the final model Values from bootstrap analysis 
Parameter Mean SE Median
2.5th 
percentile
97.5th 
percentile 
TVCL (l/h/857.3g) 0.350 0.036 0.347 0.285 0.430 
TVV (l/857.3g) 0.329 0.014 0.329 0.305 0.357 
BSV on CL (CV%) 32.6 15.8 31.1 19.2 38.2 
BSV on V(CV%) 11.6 7.1 11.0 5.5 14.5 
Proportional 
residual error
0.07 0.05 0.07 0.04 0.10 
CL-V covariance 0.521 0.220 0.513 –0.230 0.686 
TV – population typical parameter value; BSV – between subject variability; CL – clearance; V – 
volume of distribution; SE – standard error; CV% – presented as coefficient of variation, calculated 
as: (square root of ω2)·100%. 
 
GOF plots of the final PK model showing the correlation between the model-
predicted and observed plasma concentrations and time- and concentration-
independence of residual variability are presented in Figure 5, and a VPC 
showing all the observed concentration within the confidence intervals of model 
predictions is presented in Figure 6. 
 
Figure 5. Basic goodness-of-fit plots of the final PK model: A observed versus 
population predicted milrinone concentrations, B observed versus individual predicted 
milrinone concentrations, C absolute value of individual weighted residuals (|iWRES|) 
versus individual predictions, D conditional weighted residuals over time. 
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All measured plasma concentrations at 3 hr exceeded the target concentration 
range of 150–200 μg/l from the milrinone simulation study, and in 9 of 10 
patients, the plasma concentration decreased over the maintenance phase. The 
discordance can be explained by a significant reduction in total body water 
(accompanied by proportional weight loss) within the first 3–4 days of life, 
resulting in a lower volume of distribution for water-soluble agents and rapid 
changes in GFR and renal secretion within the first weeks of life (Bauer et al. 
1989; Chen et al. 2006; Pacifici 2009). Consequently, the dosing of milrinone, 
based on the milrinone simulation study using the milrinone population PK model 
developed in preterm neonates within the first days of life (Paradisis et al. 2007), 
resulted in higher than expected loading and lower maintenance concentrations 
in the population with a PNA of 5–27 days. The lower population mean volume 
of distribution (0.329 vs 0.512 l) and higher clearance (0.350 vs 0.035 l/h) found 
in our study are in concordance with this explanation. 
The differences in milrinone PK parameter estimates between two populations 
of preterm neonates studied at different ages underline the importance of 
collecting data in neonates of different GA and PNA to adequately describe the 
maturation of PK properties. A standardised GFR maturation function can be 
applied to the description of the PK of drugs mainly cleared by the kidneys. 
 
Figure 6. Visual predictive check (VPC) of 1,000 simulated milrinone concentration-
time data sets from the final model. Open circles represent the observations, a solid line 
the 50th percentile, dashed lines the 2.5th and 97.5th percentiles, and shaded areas the 95% 
confidence intervals of the corresponding predicted milrinone concentrations. 
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5.2.3 Simulation results for milrinone dose optimisation 
The best probability of concentration target (150–250 μg/l ) attainment was 
achieved with a 3-hour loading dose of 0.50 μg/kg/min followed by a main-
tenance infusion rate of 0.15 μg/kg/min. Differentiation of maintenance doses by 
PMA improved PTA from 0.561 to 0.589, with a PMA threshold of 27 weeks and 
maintenance doses of 0.15 and 0.20 μg/kg/min, in the PMA<27 and PMA≥27 
groups, respectively. Figure 7 shows the simulated milrinone plasma concen-
trations of 1,000 subjects with uniform and PMA-based maintenance doses. 
Application of a higher maintenance dose (0.20 instead of 0.15 μg/kg/min) for 
neonates with a PMA greater than or equal to 27 weeks reduced the proportion 
of patients with simulated plasma concentrations below 100 μg/l, at the cost of 
higher proportions exceeding 300 μg/l.  
As the present milrinone PK model was developed based on data from a small 
population of 10 neonates, external validation of the model and suggested dosing 
regimen would be necessary to improve the reliability. 
 
Figure 7. Simulated milrinone concentration-time curves: A 3-hour 0.5 μg/kg/min 
loading dose followed by a 21-hour maintenance dose of 0.15 μg/kg/min; B 3-hour 
0.5μg/kg/min loading dose followed by a 21-hour maintenance dose of 0.15 μg/kg/min 
in subjects under 27 weeks of PMA and 0.2 μg/kg/min in subjects with a PMA≥27 weeks. 
The lines show 2.5%, 50% and 97.5% percentiles of the simulated concentrations, shaded 
areas show bootstrapped 95% confidence intervals, and dotted grey lines mark the target 
concentration of 150–250 μg/l. 
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 5.2.4 Clinical outcome and safety of the milrinone PK study 
None of the study patients developed PLCS, defined as low systolic BP requiring 
one or more cardiotropic agents accompanied by ventilation or oxygenation 
failure. There was no significant overall LVO improvement observed at 3 hr of 
milrinone infusion, but at 24 hr of treatment, LVO improved in all but two 
patients by an average (SD) of 54 (64) ml/kg/min (p=0.037). Intra- and inter-
observer variability (mean ±SD) of LVO measurements were 10±5 ml/kg/min 
(6±4 %) and 37 ± 43 ml/kg/min (15±16%), respectively.  
Tachycardia (HR >200 min–1), registered in 3 patients during milrinone 
therapy with cumulative time over the threshold of 6, 3 and 37 min, respectively, 
triggered no change in treatment. Arterial hypotension (MAP < 30 mmHg) was 
registered in 6 patients with cumulative time under the threshold of 21, 327, 183, 
13, 101 and 30 min, respectively. Vasoactive treatment was started in two cases, 
and one patient was already on dopamine with no increase in dose during 
milrinone treatment. In both cases of additional vasoactive treatment, milrinone 
concentrations at 3 hours of therapy exceeded 300 μg/l, and the neonates had a 
PMA of less than 27 weeks. One patient with thrombocytopenia (platelet count 
< 100 × 109 /l) present prior to PDA ligation was treated with platelet transfusion. 
 
 
5.3 Dobutamine PKPD study results (Study III) 
5.3.1 Demographics of the dobutamine PKPD study population 
We recruited 31 neonates, and data from 28 were included in the final analysis. 
The reason for exclusion from the final analysis was therapeutic hypothermia in 
two cases, considered to possibly affect the PK of dobutamine, and withdrawal 
of parental consent in one case. Demographic and clinical data of the study 
patients at recruitment are presented in Table 6. The main underlying diagnoses 
were respiratory distress syndrome (n=14), early onset neonatal sepsis (n=8), 
perinatal asphyxia (n=2), meconium aspiration (n=2) and feto-fetal transfusion 
syndrome (n=2). 
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Table 6. Demographic and clinical data of the study population. Data are presented as median 
(range) or count (percent of the population), if not stated differently. 
Patient characteristics (n=28) Values 
Demographic data  
GA at birth, weeks 30.4 (22.7–41.0) 
      GA <28 weeks 7 (25%) 
      GA 28–32 weeks 9 (32%) 
      GA 32–37 weeks 7 (25%) 
      GA >37 weeks 5 (18%) 
Gender, male 18 (64%) 
BW, g 1618 (465–4380) 
Age at recruitment, hours 6 (2 – 28) 
Birth history  
Multiple birth 6 (21%) 
Small for GA 2 (7%) 
Born from Caesarean section 22 (79%) 
SNAPPE II score 16 (3–89) 
Apgar score at 5’ 7 (1–8) 
Antenatal glucocorticoids (% of neonates born <34 weeks of GA) 15 (71%) 
Laboratory data at recruitment  
Haemoglobin, g/l 163 (117–203) 
Albumin, g/l 27.7 (21.6–41.3) 
pH 7.327 (7.137–7.536) 
HCO3, mmol/l 19.1 (15.2–24.9) 
Concomitant medications  
Dopamine 5 (18%) 
Caffeine 5 (18%) 
Opiates 6 (21%) 
Sedatives 5 (18%) 
Nitric Oxide inhalation 1 (4%) 
Ventilation support at recruitment  
Invasive ventilation/FiO2 23 (82%)/0.30 (0.21–1) 
Non-invasive ventilation or nasal CPAP/FiO2 5 (18%)/0.25 (0.21–0.6) 
Circulatory status at recruitment  
RVO, ml/kg/min 136 (75–306) 
LVO, ml/kg/min 128 (71–338) 
LVEF, % 64 (51–79) 
n-number; GA – gestational age; BW – birth weight; SNAPPE II – Score for Neonatal Acute Physiology 
Perinatal Extension; RVO-right ventricular output; LVO – left ventricular output; LVEF – left ventricular 
ejection fraction
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5.3.2 Pharmacokinetics of dobutamine 
The maximum dobutamine dose was 10, 15 and 20 μg/kg/min in one, 17 and 10 
patients, respectively, with a median (range) infusion duration of 3.5 (1.4–17.7) 
days. A total of 119 dobutamine plasma concentrations were collected. In two 
samples, dobutamine was not detected, and in nine samples, the dobutamine 
concentration remained below LLOQ. The maximum measured concentration 
was 330 μg/l. The dose-concentration graph is shown inFigure 8. 
 
 
Figure 8. Measured dobutamine plasma concentrations at different continuous infusion 
rates; each colour refers to a patient. 
 
The PK data was well described by one-compartmental linear structural model 
with a proportional error model for residual variability. Michaelis-Menten 
elimination did not improve fit to the observed data. Combining the Michaelis-
Menten process parallel to linear elimination in the PK model resulted only in a 
slightly better fit (ΔOFV=10) with estimated mean (SE) values for Vmax and KM 
of 436(351) μg/h and 192(131) μg/l, respectively. Therefore, to avoid over-
parameterisation, a linear PK model was carried forward to PKPD modelling.  
Adding allometric weight scaling and the clearance maturation function 
significantly improved model fit (ΔOFV=26 and 15, respectively) and lowered 
BSV by 62%, without further improvement by other covariates. 
The final linear PK model parameter estimates from NONMEM and bootstrap 
analysis are presented in Table 7. GOF plots show population and individual 
predicted vs. observed dobutamine concentrations, as well as residuals errors 
depending neither on individual predicted concentrations, nor time (Figure 9). 
Prediction corrected VPC is presented in Figure 10
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Table 7. Final dobutamine pharmacokinetic model parameter estimates with uncertainty 
from NONMEM output file and from bootstrap analysis results. 
 Values from the final model Values from bootstrap analysis 
Model parameters Mean (SE) Shrinkage Median
2.5th 
percentile
97.5th 
percentile 
TVCL (l/h/1618 g) 41.2 (44.5) – 27.4 15.8 55.1 
TVV (l/1618 g) 5.29 (0.821) – 5.1 3.5 6.8 
BSV of CL and V 
(CV%) 
29% 
(17.2%)
17% 27 14 38 
Shared BSV scale factor 1.34 (0.373) – 1.3 0.5 3.1 
Hill 2.67 (1.90) – 4.3 1.9 33.0 
PMA50 (weeks) 37.4 (30.6) – 28.2 22.7 44.1 
Residual error 
(proportional)
0.581 
(0.229)
5% 0.316 0.231 0.433 
TV – population typical parameter value; CL – clearance ; V – volume of distribution; BSV – 
between subject variability; CV% – presented as coefficient of variation, calculated as: (square root 
of ω2)·100%; Hill – the sigmoidicity coefficient of maturation of CL; PMA50 – the PMA when the 
maturation of the CL reaches 50% of adult values. 
 
Figure 9. Basic goodness-of-fit plots of the final dobutamine linear PK model: A 
observed versus population predicted dobutamine plasma concentrations, B observed 
versus individual predicted dobutamine plasma concentrations, C absolute value of 
individual weighted residuals (|iWRES|) versus individual predictions, D conditional 
weighted residuals (CWRES) over time (log-scale). 
A
Population predictions (µg/ L)
O
bs
er
ve
d 
co
nc
en
tra
tio
ns
 (µ
g/
L)
0
100
200
300
0 50 100 150
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
● ●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
● ●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
● ●●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
B
Individual predictions (µg/ L)
O
bs
er
ve
d 
co
nc
en
tra
tio
ns
 (µ
g/
L)
0
100
200
300
0 50 100 150 200
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
● ●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
● ●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
● ●●
●
●
●
●
●
●
● ●
●
●
● ●
●
●
● ●
●
●
●
●
●
●
●
●
●
C
Individual predictions (µg/ L)
|iW
R
ES
|
0.0
0.5
1.0
1.5
2.0
0 50 100 150 200
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
● ●
D
Time (h)
C
W
R
ES
−2
−1
0
1
2
1 10 100
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
● ●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●●
●
●
●
●
●
●
●
● ● ● ●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●● ●
●
● ●
● ●
●
61 
 
Figure 10. Prediction corrected visual predictive check (VPC) of 1,000 simulated 
dobutamine concentration-time datasets from the final linear PK model. Open circles 
represent the observations, solid line the 50th percentile, dashed lines the 2.5th and 97.5th 
percentiles, and shaded areas the 95% confidence intervals of the corresponding predicted 
dobutamine concentrations. 
 
This is the first study to show how dobutamine’s clearance is related to body size 
and PMA; that could be expected based on the neonatal PK data of other 
medications but had remained undetectable in early dobutamine PK studies 
(Martinez et al. 1992).  
In previous paediatric studies, an extremely wide BSV in dobutamine plasma 
clearance has been noticed and explained by variation in sulfoconjugation and 
renal function (Berg, Padbury et al. 1993; Berg et al. 1997; Habib et al. 1992).  
We have chosen an approach in which the whole elimination process 
maturation is described by the Hill model, with estimated mean parameter values 
of 37.4 weeks for PMA50 and 2.67 for the Hill coefficient, similar to those 
identified for clearance maturation in other drugs in neonates (Germovsek et al. 
2017). 
Adding PNA did not improve the PK model fit with our data, but we would 
suggest addressing this again in future studies. The reason why we could not show 
a significant effect may be the relatively small study population within a narrow 
range of PNAs. 
In previous paediatric studies, an extremely wide BSV in dobutamine plasma 
clearance has been noticed and explained by variation in sulfoconjugation and 
renal function (Berg, Padbury et al. 1993; Berg et al. 1997; Habib et al. 1992).  
We have chosen an approach in which the whole elimination process 
maturation is described by the Hill model, with estimated mean parameter values 
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of 37.4 weeks for PMA50 and 2.67 for the Hill coefficient, similar to those 
identified for clearance maturation in other drugs in neonates (Germovsek et al. 
2017). 
Adding PNA did not improve the PK model fit with our data, but we would 
suggest addressing this again in future studies. The reason why we could not show 
a significant effect may be the relatively small study population within a narrow 
range of PNAs. 
There is one study that reports a highly variable volume of distribution of 
dobutamine with a mean (range) of 1.14 (0.09 to 5.65) l/kg in paediatric patients 
aged 1 month to 16 years of age (Schwartz et al. 1991). The mean value is higher 
than reported in adults (0.202 l/kg) (Kates et al. 1978). The typical value for the 
volume of distribution of 5.29 l/1618 g or 3.27 l/kg in the present study population 
is even higher than that reported in the paediatric study (Schwartz et al. 1991). 
A higher volume of distribution of water-soluble agents in neonates in their first 
days of life can be explained by significantly higher total body water content, 
which undergoes major reduction (accompanied by proportional weight loss) 
within the first 3 to 4 days of life (Bauer et al. 1989; Pacifici 2009), as also 
described for milrinone in the present thesis. In our study, the continuous 
administration of medication and small available cumulative PK sample volume 
limited the yield of informative data for the individual volume of distribution 
estimation. The PK model development process showed high correlation between 
BSV of clearance and volume of distribution; consequently, the common BSV 
estimate was given for clearance and the volume of distribution of dobutamine. 
Our approach yielded a shared BSV coefficient of 29% for clearance and volume 
of distribution, which is notably smaller than what was described earlier for 
dobutamine clearance or the volume of distribution.  
 
 
5.3.3 Pharmacodynamics of dobutamine 
Echocardiography measurements (RVO, LVO and LVEF) were obtained for 27 
of the 28 study patients at all timepoints; one patient only had baseline LVEF 
measured. The maximum values of RVO, LVO and LVEF achieved during 
dobutamine infusion significantly exceeded pre-treatment values: RVO increased 
from 136 (75–306) to 182 (100–442) ml/kg/min, LVO from 128 (71–338) to 162 
(94–350) ml/kg/min, and LVEF from 63.5 (51–79) to 69.5 (59–92) % (p-value 
< 0.01 in all cases). Intra- and inter-observer variability for echocardiography 
measurements are presented in Table 8. The variation of individual trends of 
RVO and LVO are shown in Figure 11. 
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Table 8. Intra- and inter-observer variability of echocardiography measurements, presented 
as absolute and relative variability. 
Measurement
Intra-observer variability Inter-observer variability 
Mean SD Mean% SD% Mean SD Mean% SD% 
RVO (ml/kg/min) 7 4 4 2 16 14 11 10 
LVO (ml/kg/min) 5 5 4 3 18 14 12 10 
LVEF (%) 4 3 5 5 2 1 3 2 
RVO – right ventricular output; LVO – left ventricular output; LVEF – left ventricular ejection 
fraction; Mean – mean absolute difference (in original units ml/kg/min); SD – standard deviation 
of absolute difference; Mean% – mean relative difference (difference between the two 
measurements as a percentage of the mean of the two measurements); SD% – standard deviation 
of relative difference. 
 
Figure 11. Individual right (blue) and left (red) ventricular cardiac output (RVO, LVO) 
measures during dobutamine dose escalation. Every numbered plot refers to a study 
patient, and every point refers to a measurement at doses 0, 5, 10, 15 and 20 μg/kg/min, 
if administered. Patient nr. 20 did not have any RVO or LVO measurements done. 
 
We described the concentration-related effect of dobutamine on RVO, LVO, 
LVEF, HR, MAP and cFTOE. OFVs of all the tested PKPD models with different 
PD model structures are presented in Table 9. Residual variability for both 
concentration and effect were best described with a proportional error model, 
remaining >50% in PK observations and between 5–20% in PD observations.
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Table 9. Objective function values of tested pharmacokinetic-pharmacodynamic models. 
PD model 
structure RVO LVO LVEF HR
HR+
KEO MAP
MAP+
KEO cFTOE 
cFTOE
+KEO 
linear 1849 1806 1451 7655 7598 5418 5418 –5080 –5108 
Emax 1847 1801 1451 7654 7513 5240 5145 –5288 –5139 
sigmoidal Emax 1847 1797 1451 7457 7411 5076 5101 –5567 –5152 
RVO – right ventricular output; LVO – left ventricular output; LVEF – left ventricular ejection 
fraction; HR – heart rate; KEO – equilibration rate constant between effect and observed (plasma) 
compartment, indicating that effect compartment was added to the model; MAP – mean arterial 
blood pressure; cFTOE – cerebral fractional oxygen extraction; the underlined objective function 
values indicate the final models. 
 
Changes in RVO and LVEF were best described with linear PD models and in 
LVO with a sigmoidal Emax model with an estimated mean (SD) EC50 of 117 
(37.0) μg/l. The linear concentration-effect relationship within the studied 
concentration range for RVO, LVEF and the relatively high mean EC50 estimate 
for LVO suggest improvement of cardiac function and central blood flow 
throughout the studied dose range. 
Final RVO, LVO and LVEF PKPD model parameter estimates together with 
values from bootstrap analysis are presented in Table 10. GOF plots of con-
centration and effect predictions are presented in the Appendix (Figures A1–A3) 
and predictions corrected VPC plots in Figure 12. 
 
Table 10. Right ventricular output (RVO), left ventricular output (LVO) and left 
ventricular ejection fraction (LVEF) pharmacokinetic-pharmacodynamic model final 
parameter estimates with uncertainty from the NONMEM output file and from the 
bootstrap analysis. 
Model parameters 
Values from the final 
model
Values from bootstrap  
analysis
Mean (SE) Shrinkage Median
2.5th 
percentile
97.5th 
percentile 
RVO  
TVCL (l/h/1618 g) 41.0 (3.15) – 41.0 35.2 48.2 
TVV (l/1618 g) 5.31 (0.753) – 5.1 3.5 7.0 
BSV of CL and V 
(CV%) 
27% (18.7%) 18% 25 13 37 
Shared BSV scale 
factor 
1.50 (0.479) – 1.5 0.6 3.7 
TVE0 (ml/kg/min) 151 (12.8) – 151 127 180 
BSV of E0 (CV%) 41% (22.2%) 3% 41 29 50 
TVSL 0.214 (0.067) – 0.214 0.061 0.386 
PK residual error 
(proportional)
0.583 (0.052) 8% 0.575 0.484 0.664 
PD residual error 
(proportional)
0.184 (0.014) 8% 0.182 0.163 0.200 
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Model parameters 
Values from the final 
model
Values from bootstrap  
analysis
Mean (SE) Shrinkage Median
2.5th 
percentile
97.5th 
percentile 
LVO  
TVCL (l/h/1618 g) 40.7 (3.03) – 41.0 34.9 47.6 
TVV (l/1618 g) 5.14 (0.726) – 5.0 3.4 6.6 
BSV of CL and V 
(CV%) 
25% (17.5%) 21% 24 11 34 
Shared BSV scale 
factor 
1.33 (0.490) – 1.3 0.4 3.6 
TVE0 (ml/kg/min) 131 (9.64) – 131 114 151 
BSV of E0 (CV%) 36% (19.8%) 3% 35 25 45 
TVγ 2.82 (1.25) – 3.3 1.0 7.3 
TVEC50 (μg/l) 117 (37.0) – 110.4 80.6 217.3 
TVEmax (ml/kg/min) 157 (21.8) – 155 119 200 
BSV of Emax (CV%) 44% (39.7%) 29% 38 11 79 
PK residual error 
(proportional)
0.589 (0.053) 11% 0.576 0.493 0.670 
PD residual error 
(proportional)
0.167 (0.015) 11% 0.164 0.138 0.191 
LVEF  
TVCL (l/h/1618 g) 41.2 (3.22) – 41.0 35.1 47.5 
TVV (l/1618 g) 5.26 (0.753) – 5.0 3.4 6.9 
BSV of CL and V 
(CV%) 
28% (19.3%) 17% 26 15 37 
Shared BSV scale 
factor 
1.38 (0.434) – 1.4 0.6 3.4 
TVE0 (%) 63.5 (1.46) – 63.6 60.6 66.3 
BSV of E0 (CV%) 9% (5.6%) 10% 9 7 11 
TVSL 0.029 (0.015) – 0.029 0.008 0.053 
PK residual error 
(proportional) 
0.580 (0.051) 7% 0.571 0.486 0.660 
PD residual error 
(proportional) 
0.098 (0.007) 7% 0.096 0.063 0.141 
TV – population typical parameter value; BSV – between subject variability; CV% – presented as 
coefficient of variation, calculated as: (square root of ω2)·100%; CL – clearance; V – volume of 
distribution; E0 – estimated baseline value of PD parameter; SL – slope of the linear relationship 
between effect and concentration; E0 – estimated baseline value of PD parameter; γ – steepness of 
concentration-effect relationship; EC50 – concentration at half-maximal effect; Emax – the estimated 
maximum value of the PD parameter.  
Table 10. (continued)
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Figure 12. Prediction corrected visual predictive checks (VPC) of 1,000 simulated 
concentration-time and effect-time datasets from the dobutamine final pharmacokinetic-
pharmacodynamic models of: A right ventricular output (RVO), B left ventricular output 
(LVO), C left ventricular ejection fraction (LVEF), D heart rate (HR), E mean arterial 
blood pressure (MAP), F cerebral fractional tissue oxygen extraction fraction (cFTOE). 
Circles represent the observations, solid line the 50th percentile, dashed lines the 2.5th and 
97.5th percentiles, shaded areas the 95% CIs of the corresponding model predicted values. 
 
Dobutamine’s effect on HR was best described by a model with an effect com-
partment equilibration rate constant with mean effect time of 9 min (keo–1 ∙60 min) 
and sigmoidal Emax PD model with an estimated mean (SD) EC50 of 39.2 
(5.56) μg/l. The change in MAP during dobutamine treatment was described by a 
sigmoidal Emax model without an effect compartment equilibrium rate constant 
with an estimated mean (SD) EC50 of 25.4 (2.00) μg/l. The decrease in cFTOE 
was described by a sigmoidal Emax model without an effect compartment equi-
librium rate constant with an estimated mean (SD) EC50 of 52.9 (7.26) μg/l. The 
observed lower mean EC50 estimates (25–53 μg/l) and steep concentration-effect 
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relationship (ϒ of 3.4–13.5) for HR, MAP and cFTOE indicate that these changes 
take place at lower dobutamine concentrations and are limited.  
Parameter estimates of HR, MAP and cFTOE final PKPD models from 
NONMEM and bootstrap analysis are presented in Table 11, GOF plots of con-
centration and effect predictions in the Appendix (Figures A4–A6) and prediction 
corrected VPC plots in Figure 12.  
The BSV coefficient estimates of clearance and the volume of distribution 
were the lowest in the PKPD models of LVO and MAP effect, 25 and 24%, 
respectively (Table 10 and Table 11). These results point towards the possible 
impact of CO and BP on the elimination rate of dobutamine.  
 
Table 11. Heart rate (HR), mean arterial blood pressure (MAP) and cerebral fractional 
tissue oxygen extraction (cFTOE) pharmacokinetic-pharmacodynamic model final 
parameter estimates with uncertainty from the NONMEM output file and from the 
bootstrap analysis. 
Model parameters 
Values from the final 
model
Values from bootstrap  
analysis
Mean (SE) Shrinkage Median
2.5th 
percentile 
97.5th 
percentile 
HR  
TVCL (l/h/1618 g) 42.3 (3.22) – 40.6 34.9 47.5 
TVV (l/1618 g) 5.42 (0.766) – 5.2 3.4 6.9 
BSV of CL and V 
(CV%) 
27% (18.0%) 15% 25 14 36 
Shared BSV scale 
factor 
1.72 (0.421) – 1.8 0.7 4.7 
TVE0 (min–1) 138 (4.2) – 138 130 146 
BSV of E0 (CV%) 15% (8.1%) 4% 15 9 21 
TVKE0 (h–1) 6.59 (2.18) – 6.2 3.8 8.7 
γ 3.36 (0.326) – 3.4 2.7 8.0 
TVEC50 (μg/l) 39.2 (5.56) – 38.5 29.5 48.9 
BSV of EC50 (CV%) 50% (32.2%) 21% 47 22 66 
TVEmax (min–1) 172 (2.5) – 171 158 177 
BSV of Emax (CV%) 5% (3.1%) 28% 5 2 11 
PK residual error 
(proportional)
0.590 (0.052) 3% 0.582 0.498 0.682 
PD residual error 
(proportional)
0.051 (0.001) 3% 0.050 0.033 0.070 
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Model parameters 
Values from the final 
model
Values from bootstrap  
analysis
Mean (SE) Shrinkage Median
2.5th 
percentile 
97.5th 
percentile 
MAP 
TVCL (l/h/1618 g) 37.2 (2.88) – 37.4 31.9 45.0 
TVV (l/1618 g) 4.88 (0.958) – 4.8 3.3 6.5 
BSV of CL and V 
(CV%) 
24% (16.6%) 4% 25 10 40 
Shared BSV scale 
factor 
3.62 (0.760) – 3.5 1.9 8.9 
TVE0 (mmHg) 39.7 (1.75) – 39 36 43 
BSV of E0 (CV%) 22% (11.8%) 2% 22 17 26 
TVγ 13.5 (2.94) – 13.5 7.1 21.7 
TVEC50 (μg/l) 25.4 (2.00) – 25.5 17.4 34.9 
TVEmax (mmHg) 41.9 (2.19) – 41 37 47 
BSV of Emax (CV%) 26% (13.9%) 4% 26 19 31 
PK residual error 
(proportional)
0.675 (0.062) 2% 0.666 0.551 0.827 
PD residual error 
(proportional)
0.065 (0.001) 2% 0.064 0.049 0.081 
cFTOE  
TVCL (l/h/1618 g) 37.2 (3.61) – 37.4 31.0 47.0 
TVV (l/1618 g) 4.80 (0.993) – 4.5 3.2 6.0 
BSV of CL and V 
(CV%) 
35% (21.5%) 9% 32 10 46 
Shared BSV scale 
factor 
2.42 (0.333) – 2.3 0.7 6.5 
TVE0 (mmHg) 0.227 (0.023) – 0.224 0.182 0.271 
BSV of E0 (CV%) 50% (26.8%) 2% 50 30 74 
TVγ 3.65 (0.573) – 3.9 1.2 23.1 
TVEC50 (μg/l) 52.9 (7.26) – 50.8 18.9 93.2 
TVEmax (mmHg) 0.206 (0.027) – 0.208 0.147 0.260 
BSV of Emax (CV%) 60% (36.2%) 9% 55 38 88 
PK residual error 
(proportional)
0.653 (0.061) 2% 0.633 0.528 0.774 
PD residual error 
(proportional)
0.181 (0.004) 2% 0.179 0.139 0.217 
TV – population typical parameter value; BSV – between subject variability; CV% – presented as 
coefficient of variation, calculated as: (square root of ω2)·100%; CL – clearance; V – volume of 
distribution; E0 – estimated baseline value of PD parameter; γ – steepness of concentration-effect 
relationship; KE0 – the equilibration rate constant between effect and observed (plasma) 
compartments; EC50 – concentration at half-maximal effect; Emax – the estimated maximum value 
of the PD parameter
Table 11. (continued)
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The effect of dobutamine on CO was found to increase throughout the studied 
dose range at least up to a concentration of 200 μg/l. The improvement of CO 
beyond the maximum HR effect implicates the role of improved myocardial 
function and/or decreased SVR. 
Unfortunately, there are no studies to compare our results with that report the 
dobutamine concentration-related increase in HR in neonates. However, according 
to the review by Mahoney et al., previous studies also report only a moderate 
average increase (up to 11,6%) in heart rate with dobutamine treatment, even with 
a dose of 20 μg/kg/min (Devictor et al. 1988; Klarr et al. 1994; Mahoney et al. 
2016; Osborn et al. 2002; Robel-Tillig et al. 2007; Roze et al. 1993; Stopfkuchen 
et al. 1987, 1990). Hence tachycardia is unlikely to limit the dobutamine’s effect 
on CO, and increasing dose up to 20 μg/kg/min appears to be feasible. 
The change in BP during dobutamine treatment has also shown to be moderate 
in previous studies, and the maximal increase tends to be reached with doses of 
5–10 μg/kg/min (Devictor et al. 1988; Klarr et al. 1994; Mahoney et al. 2016; 
Martinez et al. 1992; Osborn et al. 2002; Robel-Tillig et al. 2007; Roze et al. 
1993; Ruelas-Orozco et al. 2000). Martinez et al. showed in one patient that the 
dobutamine plasma concentration threshold for systolic BP increase is much 
lower than for CO, although the measured plasma concentrations were much 
lower than in our study, 8 and 35 μg/l, respectively (Martinez et al. 1992). 
The increase rather than decrease of MAP in response to dobutamine is 
potentially explained by developmental differences in vascular α- and β-AR 
expression. During early development, cardiovascular α-AR expression is 
upregulated while maturation of β-AR lags behind, and preterm neonates are 
likely to respond to dobutamine with attenuated decreases in systemic vascular 
resistance and thus with a more pronounced increase in BP (Felder et al. 1983; 
Noori et al. 2012). 
In previous studies, dobutamine has also been shown to increase superior vena 
cava flow, which is considered to reflect cerebral blood flow (Bravo et al. 2015; 
Osborn et al. 2002). The increase of blood flow velocities and decrease of the 
pulsatility index of the anterior cerebral artery is shown by Robel-Tilling et al. in 
20 neonates with myocardial dysfunction (Robel-Tillig et al. 2007). The present 
study describes dobutamine’s effect on cFTOE as a surrogate for cerebral blood 
flow. The modest decrease in cFTOE may refer to an increase in cerebral blood 
flow already at a relatively low plasma concentration. 
Neonatal circulatory management is aimed at preventing cerebral hypoper-
fusion, particularly in preterm neonates in whom cerebral autoregulation may be 
impaired or absent. Although the role of inotropes in the prevention of prema-
turity-related brain injury has been difficult to establish, there is some evidence 
that early administration of dobutamine may be relatively safe (Brew et al. 2018). 
In a study in preterm neonates with short- and long-term follow ups, dobutamine 
was found to be associated with a greater increase in systemic blood flow, 
reduced rates of severe IVH and fewer disabilities at 3 years of age, but similar 
combined rates of death or disability were found in infants treated with dopamine 
(Osborn et al. 2007, 2002). 
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A concentration-dependent increase in CO has been previously described by 
Martinez et al. in 13 critically ill neonates. They showed an average (standard error, 
SE) increase of 25% in CO, from 205 (13) to 256 (12) ml/kg/min. Dobutamine was 
administered in doses up to 7.5 μg/kg/min, and most of the measured plasma 
concentrations remained below 100 μg/l (Martinez et al. 1992). In our study, the 
average baseline CO was lower, 151(12.8) and 131(9.64) ml/kg/min for RVO and 
LVO, respectively, and the average CO remained below 200 ml/kg/min even with 
dobutamine plasma concentrations up to 200 μg/l. Nevertheless, the proportional 
change in CO was found to be similar: 20–30%. 
High BSV of the PD response suggests the need for individual dose titration 
rather than targeting a specific dosing regimen in neonates receiving dobutamine 
for stabilisation of transitional circulation. 
 
 
5.3.4 Clinical outcome and safety of the dobutamine PKPD study 
14 of the 28 study patients had 21 serious adverse events (SAE) during the study 
follow-up period. Four study patients died, and the fatal SAEs were gastric 
perforation, necrotising enterocolitis with intestinal perforation, pulmonary 
interstitial emphysema and pulmonary interstitial emphysema combined with 
haemolysis and pulmonary hypertension. Deterioration of respiratory status 
requiring intubation with invasive ventilation occurred in two and intestinal 
perforation in two patients, and one patient had ileus as a complication of surgery 
for anal atresia. None of the aforementioned SAEs were considered to be related 
to dobutamine. 
Twenty-seven patients had cerebral ultrasonography performed within the 
follow up period, IVH grade III–IV occurred in two, grade I–II in four, 
periventricular leukomalacia in three and other intracranial pathologies in three 
patients. The incidence is comparable to that of previous studies (Alderliesten et 
al. 2013; Osborn et al. 2003). 
The high incidence of SAEs and mortality reflects that we have conducted the 
study in critically ill neonates in the true dobutamine use clinical scenario. 
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6. GENERAL DISCUSSION 
Cardiovascular PKPD data in neonates is sparse, and extrapolating information 
between different maturational stages PMA- or PNA-wise, as well as between 
different clinical situations, could lead to a significant offset in clinical results 
(Allegaert, Simons et al. 2017; van den Anker et al. 2018). Therefore, the PK and 
PD properties of medications should be properly understood in the particular 
populations and clinical situations in which they are used.  
 
 
6.1 Challenges in neonatal pharmacokinetic-
pharmacodynamic research 
Planning and conducting neonatal pharmacological studies involve many chal-
lenges. Working with a vulnerable population with an urgent need to start treat-
ment makes the study recruitment process and obtaining informed consent dif-
ficult and demanding for the medical staff (Harter et al. 2016). In a situation in 
which treatment needs to be started immediately, informing the parents in an 
emotionally difficult situation is not an easy task for the researchers and puts 
additional pressure on the parents.  
The fact that the medications are studied in situations in which they are 
prescribed on clinical indication likely makes it easier for parents to accept their 
baby’s participation in the study (Baker et al. 2005; Tooher et al. 2008). That was 
the case in the present studies in which we investigated the PK and PD of the 
studied medications in situations when the treating physician believed them to be 
the best treatment choice for the patient. The parents were informed about the 
need to collect more detailed information about the studied medication, perform 
some additional monitoring and haemodynamic measurements and to collect 
some extra blood for concentration measurements. The need to collect and 
analyse data with the intent to have more precise treatment abilities in the future 
was well understood by the parents. 
However, future developments should also carefully account for the potential 
benefits of deferred consent or other alternative approaches to “unload” parents, 
especially in situations already holding huge emotional stress for them (McCarthy 
et al. 2019; Megone et al. 2016; Rich et al. 2019). Increasing patient-parent 
involvement in planning clinical research may help to reach good consensus. 
Very limited acceptable cumulative sampling volume in ELBW infants requires 
analytical methods for a minimal sample volume and excellent knowledge and 
analytical skills to optimise the sampling times to get most of the sparse data 
(Committee for Medicinal Products for Human Use (CHMP) et al. 2008). 
Lack of standardised acute period outcome parameters and a small signal-to-
noise ratio makes acquiring HD data for PKPD modelling a complex and chal-
lenging process. The need for simultaneous application of different monitoring 
techniques further adds to complexity. The feasibility of simultaneous recording 
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from different monitoring devices, ultrasound and PK sampling and the reliability 
of the data acquirement systems may need to be tested in pilot studies. To test the 
applicability of the HD monitoring, data acquisition methods and repeated echo-
cardiography procedures, we performed a pilot study with 10 participants (Hallik 
et al. 2015). 
While the technical challenges are likely to be alleviated by fast development 
of technology, ensuring maximum information gain through data repositories and 
sharing is only just taking off. Furthermore, if such demanding studies are per-
formed and PK models developed and fitted, they often lack external validation. 
Validating the PK models in different populations would increase reliability and 
usefulness and would help us to standardise the covariate model structures for 
different drugs. 
 
 
6.2 Pharmacokinetic studies of cardiovascular  
medications in neonates 
If we look at the populations of paediatric PK studies of inotropes, they also 
include some (usually a few) neonates, and in most cases, the neonatal data is 
pooled together with data from older children (Bailey et al. 2004; Banner et al. 
1991; Berg et al. 1997; Gist et al. 2015; Hornik et al. 2019; Mizuno et al. 2019; 
Oualha, Tréluyer et al. 2014; Oualha, Urien et al. 2014). In populations with a 
wide age range, the maturation and development of PK parameters and covariates 
can be described more generally for the whole population age range, but the 
important rapid maturation processes within the first days and weeks of life 
remain marginal, undetectable and undescribed. The inappropriateness of extra-
polating these findings and dosing regimens to patients at the extremes of the 
weight-for-age range or ELBW infants without dedicated studies has been pointed 
out in a recent review (Allegaert, Simons et al. 2017). 
Even extrapolation of the PK data from one neonatal population to another 
may not yield appropriate and clinically applicable results. The results of our 
research (the milrinone simulation study and milrinone PK study) showed that 
using a PK model for a preterm neonatal population for dose optimisation in a 
slightly different age group of preterm neonates (difference in PNA within 
4 weeks), causes significant offset between simulated and measured concen-
trations (Figure 4). In the end, we recommended a 33% lower loading dose of 
milrinone for the PDA surgical closure population than was estimated based on 
the PK model from preterm neonates within the first days of life.  
Furthermore, with cardiovascular drugs, the PD effect can also affect PK 
processes, and PD effects can be different from those seen in older populations. 
Thus, extrapolating PK data on cardiovascular medications from adult, paediatric 
and even different neonatal studies to neonates may cause unpredictable biases 
(Allegaert, Simons et al. 2017). 
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There are a few PK studies of cardiovascular drugs in neonates describing 
milrinone PK in neonates with PPHN, after OHS, and in preterm neonates within 
the first days of life, as well as dobutamine PK in neonates (Martinez et al. 1992; 
Mc Namara et al. 2013; Paradisis et al. 2007; Zuppa et al. 2006). Most of these 
studies, including ours, are limited to specific clinical indications. We believe 
that only population PK studies focusing on particular patient populations and 
clinical situations can give us accurate information about BSV, important 
covariates and the extent of their effect on PK parameters within a specific disease 
state. However, future developments in physiology-based PK modelling will 
likely lead to merging these fragmented data into a more complex, yet detailed, 
understanding of the drug-body interactions. 
 
 
6.3 Pharmacodynamic studies of cardiovascular 
medications in neonates 
Simultaneous population PKPD modelling is a tool that can be used to improve 
our knowledge about the effects of inotropes in neonatal populations. Particularly 
in the present situation in which randomised controlled trials in many cases have 
proven unfeasible and the results of prospective observational studies describing 
the effects of antihypotensive therapy on clinical outcomes are contradictory 
(Batton et al. 2016; Bravo et al. 2015; Dempsey et al. 2014; Durrmeyer et al. 2017; 
Pellicer et al. 2009). 
Better understanding the drug-response relationship may shed some light on 
these discrepancies. For example, the hemodynamic effects and the clinical 
response to vasopressors and inotropes is altered by downregulation of adrenergic 
receptors caused by critical illness-associated prolonged endogenous and treat-
ment-associated exogenous receptor stimulation (Ruffolo et al. 1986).  
Furthermore, because cardiovascular adrenergic receptor expression is regu-
lated by corticosteroids, the documented higher incidence of relative adrenal 
insufficiency also contributes to the observed attenuated hemodynamic response 
and the development of vasopressor-dependence in preterm and term neonates 
(Davies et al. 1984; Fernandez et al. 2009). These effects, especially seen in patients 
with prolonged exposure to dopamine and other vasopressors and inotropes, 
likely have implications for long-term outcomes (Seri et al. 2001).  
Collecting and analysing PK and PD data together allows us to consider the 
clinical effectiveness of vasopressors and inotropes in a situation in which certain 
exposure to medication does not guarantee the expected PD effect. 
There are many methodological issues to be considered when planning neo-
natal PD studies of inotropes. First, the PD effect parameters are to be chosen. 
When treating haemodynamically compromised neonates, the immediate treat-
ment targets can be BP or central blood flow thresholds or prevention of regional 
tissue hypoxia. As long as we do not have evidence-based consensus on which 
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measurable HD parameters are related to short- and long-term mortality and 
morbidity, it is difficult to find ideal treatment targets.  
With more precise knowledge about how drugs act in particular situations, in 
terms of change in the HD parameter values, it will be increasingly possible to 
identify the advantages and disadvantages of these medications in terms of short- 
and long-term clinical outcomes for critically ill neonates. 
 
 
6.4 Limitations of the studies 
These studies have several limitations. First, the small number of patients in the 
milrinone PK study precluded the exploration of the impact of additional patient 
characteristics potentially affecting the PK of milrinone, including prior ibuprofen 
therapy and the status of renal function. Considering the homogenous population, 
we could give dosing recommendations only in preterm neonates without severe 
renal function impairment.  
We could not provide PD analysis, and thus the effect on blood flow and 
effectiveness of preventing PLCS of the recommended milrinone dosing scheme 
will be the objective of future studies.  
The limited number of PK samples per patient in the dobutamine PKPD study 
did not yield informative data on the volume of distribution (hence BSV could 
not be separately estimated for clearance and V). Although we tested adding 
Michaelis-Menten processes in the dobutamine PK model, having only a few PK 
samples >200 μg/l in the dataset minimised the significance of saturable elimi-
nation pathways in model fitting. The saturation of elimination pathways of 
dobutamine may become important at higher plasma concentrations, but we may 
not have been able to capture the higher end of concentrations sufficiently. 
If we could collect PKPD data from larger populations, more diverse and 
infrequent covariates such as co-medications and co-morbidities could be explored 
and their effects to PK and PD described. Although adding postnatal age, con-
comitant medications and severity of illness in covariate analysis did not improve 
the PK model fit in our study, a larger and more variable study sample may be 
needed to describe these covariate effects.  
In neonatal PK studies, an important limitation/source of residual error is drug 
administration accuracy. Dilution of the formula, low infusion rates and large 
dead space may lead to a discrepancy between the prescribed and actual infusion 
rates, resulting in a PK observation residual error of over 50% in the dobutamine 
PKPD study.  
Despite all the aforementioned limitations, we need to recognise that these 
studies were conducted in critically ill neonates in real-life conditions, with all 
the related challenges. 
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6.5 Clinical implementation and future considerations 
The main clinical importance of this research is to improve pharmacological 
treatment of haemodynamically compromised neonates based on PK and PKPD 
knowledge. 
As a result of the research, we have suggested a precise dosing regimen for 
milrinone in preterm neonates after PDA ligation. 
The results of the PKPD study of dobutamine inform us about expected HD 
responses during dobutamine administration to neonates within the transition 
period. Dobutamine can be used to increase CO in a dose up to 20 μg/kg/min 
without excessive effect to BP or HR. It can also be considered to be a proof of 
concept study, as PKPD studies of cardiovascular drugs relying on rich PD data-
sets, as in our study, are scarce in neonates. 
Future studies will have to define methods for individual dose/effect 
optimisation of cardiovascular drugs in neonates. However, today we do not know 
what immediate HD parameter effects to target for better long-term outcomes. 
Collecting and analysing the complex and multimodal HD data to predict short- 
and long-term mortality and morbidity is a research area that needs to develop 
together with the understanding of the PKPD of vasopressors and inotropes. 
Integrating continuous monitoring and analysis of multimodal HD data with 
PKPD methods may provide tools to individualise vasopressor and inotrope 
therapy in critically ill neonates. 
It is important to arrive at an agreement as to how the PK parameter maturation 
is described in the models for preterm neonates. For example, should it be based 
on PMA, which includes intrauterine and postnatal development, to which PNA-
based changes can be added, or should it incorporate GA- and PNA-based 
changes separately? Standardising model parameterisation will benefit the pae-
diatric PK community by facilitating parameter value interpretation and model 
sharing across studies (Germovsek et al. 2017). 
Through implementing PK and PD knowledge into maturational physiology, 
precise drug dosing regimens can be developed for critically ill neonates to 
optimise the efficacy and minimise the negative effects of pharmacotherapies. 
Translating and implementing the results of PKPD studies into clinical practice 
is an important task that needs to involve specialists from different fields of neo-
natal medicine, including clinical practice, research and pharmacometrics. 
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7. CONCLUSIONS 
1. Simulations suggest that the plasma time-concentration profile of milrinone 
in neonates after patent ductus arteriosus ligation could be optimized with a 
slow loading dose followed by maintenance infusion. The objective target of 
most simulations with maintenance phase plasma concentrations in the range 
of 150–200 μg/l for at least 80% of time was maximized with a 3-hour infusion 
of 0.73 μg/kg/min, followed by a 0.16 μg/kg/min maintenance dose.  
 
2. The pharmacokinetics of milrinone in premature neonates was best described 
by a one-compartmental linear model with parameters allometrically scaled to 
body weight and the age maturation function of the glomerular filtration rate 
taken into account. Rapid physiological changes during the first weeks of life 
have a significant impact on the drug metabolism – modelling the milrinone 
pharmacokinetics in the patent ductus arteriosus ligation population resulted 
in a smaller distribution volume and higher clearance when compared to 
preterm neonates in their very first days after birth. 
 
3. Our modelling and simulation results allow us to recommend two PMA-
dependent dosing regimens of milrinone for the prevention of post-ligation 
cardiac syndrome. For neonates younger than 27 weeks of PMA, a regimen of 
0.5 μg/kg/min 3-hr loading followed by a maintenance infusion of 
0.15 μg/kg/min can be recommended, while infants at least 27 weeks of PMA 
should receive a maintenance dose of 0.2 μg/kg/min after an identical loading 
dose. The effectiveness of this dosing scheme in preventing post-ligation 
cardiac syndrome needs to be elucidated in future studies. 
 
4. The pharmacokinetics of dobutamine in critically ill neonates in the first days 
of life fits with a one-compartmental linear model in which clearance and the 
volume of distribution are allometrically scaled to body weight and the model 
includes the maturation function of elimination mechanisms with post-
menstrual age. 
 
5. The effects of dobutamine on cardiac function, blood pressure and cerebral 
blood flow during transitional circulation occur at different plasma concen-
trations. The effect on the heart rate and arterial blood pressure is limited and 
saturable at lower plasma concentrations, contrary to the effect on cardiac out-
put, which continues to increase with higher plasma concentrations throughout 
the currently used dose range.  
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9. SUMMARY IN ESTONIAN 
Inotroopsete ravimite farmakokineetika ja  
farmakodünaamika vastsündinutel 
Vastsündinueaks loetakse inimese esimesed 28 elupäeva. See lühike ajaperiood 
hõlmab väga olulisi arengulisi muutusi. Kuna vastsündinute raske haigestumise 
peamiseks riskifaktoriks on enneaegne sünd, tuleb neonatoloogidel tegeleda 
patsientidega, kes on sündinud raseduse erinevatel etappidel, kellel esineb lisaks 
ebaküpsusele ka arenguhäireid ning kelle kehakaal varieerub rohkem kui kümne-
kordselt. Lisaks kiiretele loomuliku küpsemise protsessidele kujundavad vast-
sündinute populatsiooni heterogeensust veel kriitiline haigusseisund ning inten-
siivne ravitegevus. 
Kriitlises seisundis vastsündinutel kasutatakse palju erinevaid ravimeid. 
Enamike ravimite kasutamist sellel populatsioonil ei ole piisavalt uuritud. Nii on 
näidatud, et kuni 65% vastsündinute intensiivravi osakondades kasutatavatest ravi-
mitest on nn. off-label ehk mitte litsentseeritud kasutamiseks sel vanusegrupil. 
(Nir-Neuman et al. 2018) Seejuures on just enneaegsed vastsündinud enim ekspo-
neeritud ravimitele, mille näidustused, toimed ja kõrvaltoimed ei ole piisavalt 
uuritud. (Kimland et al. 2012) Seetõttu on ravimite kasutuspraktika vastsündi-
nutel väga varieeruv ja osakonniti erinev. 
See kehtib ka südame- ja veresoonkonna ravimite kohta. Tõenduspõhisus, 
millist ravimit millises olukorras vastsündinul kasutada, millises doosis ravi alus-
tada, kuidas doosi tiitrida ning millised parameetreid ravi efektiivsuse hinda-
miseks monitoorida, on äärmiselt tagasihoidlik. (Barrington 2008; Evans 2006; 
Kluckow et al. 2008) Manustamisel orienteerutakse enamasti laste ja täiskasva-
nute meditsiinis kasutusel olevate kliiniliste sümptomite järgi: madal vererõhk, 
südamefunktsiooni langus, madal südame minutimaht, halb perifeerne vere-
varustus, vähenenud uriinieritus, laktatsidoos – kõik vereringe puudulikkuse 
tunnused. Vastsündinute südame-veresoonkonna füsioloogia ja patofüsioloogia 
on aga eripärane, mistõttu ei saa täiskasvanutel või lastel läbiviidud uuringuid 
ekstrapoleerida sellele populatsioonile. 
Matemaatiline modelleerimine on paljulubav metoodika vastsündinute farma-
kokineetika ja farmakodünaamika alasteks ravimuuringuteks. Populatsiooni-
põhine lähenemine sobib hästi andmete vähesuse ja hõredusega, mis tuleneb vast-
sündinute haavatavusest nii vereanalüüside hulga kui ka paljude invasiivsete 
monitooringumeetodite suhtes. Matemaatiline modelleerimine annab võimaluse 
kirjeldada arenguliste ja mittearenguliste kovariaatide rolli patsientidevaheliste 
erinevuste kujunemises ning selle põhjal võimaldab jõuda täpsemate patsiendi-
põhiste doseerimisskeemideni. Kui me ei tea ravimite farmakokineetika ja 
farmakodünaamika vahelisi seoseid, nende varieeruvust indiviidide vahel või ühe 
indiviidi piires ja seoste muutust tulenevalt kiirest arengust vastsündinueas, võib 
juhtuda, et efektiivsusuuringutes kasutatakse valesid doose ning potentsiaalselt 
vajalikud ravimid tunnistatakse ebaefektiivseks. (Jadhav et al. 2010) 
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Oluline on uurida ravimite farmakokineetikat ja farmakodünaamikat just 
nendes vastsündinute populatsioonides ja kliinilistes situatsioonides, kus neid 
enim kasutatakse. Käesolev doktoritöö keskendub kahele kliinilisele situat-
sioonile ja vastavatele patsiendipopulatsioonidele: vahetus sünnijärgses perioodis 
kriitilises seisundis vastsündinud, kellel uurisime dobutamiini farmakokineetikat 
ja kontsentratsioonist sõltuvat toimet südamele ja vereringele, ning arterioosjuha 
kirurgilise sulgemise järgselt pulmo-kardiaalse seisundi olulise halvenemise 
riskiga enneaegsed vastsündinud, kellel uurisime milrinooni farmakokineetikat. 
 
Uurimistöö eesmärgid 
Töö üldine eesmärk oli kirjeldada dobutamiini ja milrinooni populatsiooni 
farmakokineetikat ja farmakodünaamikat kahes kliinilises olukorras, kus neid 
ravimeid vastsündinutel sageli kasutatakse. 
 
Töö täpsemad eesmärgid olid järgmised: 
• Analüüsida seniseid teaduskirjanduses avaldatud andmeid milrinooni farma-
kokineetikast lastel ja vastsündinutel. Nende põhjal töötada välja optimaalne 
doseerimisskeem arterioosjuha kirurgilise sulgemise järgseks perioodiks, 
kasutades arvutipõhist eesmärkkontsentratsiooni saavutamise tõenäosuste 
modelleerimist. Saadud doseerimisskeemi rakendada järgnevas prospek-
tiivses uuringus. 
• Kirjeldada milrinooni farmakokineetikat enneaegsetel vastsündinutel arte-
rioosjuha kirurgilise sulgemise järgses perioodis. 
• Prospektiivses uuringus kogutud andmete põhjal anda soovitused milrinooni 
optimaalseks doseerimiseks selles situatsioonis. 
• Kirjeldada dobutamiini farmakokineetikat kriitilises seisundis vastsündinutel 
vahetus sünnijärgses perioodis. 
• Kirjeldada dobutamiini kontsentratsioonist sõltuvaid toimeid tsentraalsele ja 
regionaalsele hemodünaamikale selles situatsioonis. 
 
Uuritavad ja metoodika 
Käesoleva doktoritöö raames viidi läbi kolm uuringut: 
• Retrospektiivses uuringus koguti demograafilised andmed patsientide kohta, 
kellel tehti arterioosjuha kirurgiline sulgemine Tartu Ülikooli Kliinikumis või 
Tallinna Lastehaiglas ajavahemikul jaanuar 2012 kuni detsember 2014. 
Kasutades kirjanduses leitavaid populatsiooni farmakokineetika mudeleid, 
simuleeriti sellele populatsioonile milrinooni aja-kontsentratsiooni kõverad 
ning leiti nende põhjal doseerimisskeem, mis kõige suurema tõenäosusega 
võiks anda ravimi plasmakontsentratsiooni 150–200 μg/l 6–24 tundi peale 
arterioosjuha ligeerimist. 
• Prospektiivne uuring milrinooni farmakokineetikast patsientidel, kellel tehti 
arterioosjuha sulgemise operatsioon Tartu Ülikooli Kliinikumis või Tallinna 
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Lastehaiglas ajavahemikul juuni 2015 kuni oktoober 2017. Milrinooniga raviti 
neid patsiente, kellel üks tund peale arterioosjuha ligeerimise operatsiooni oli 
südame vasaku vatsakese väljutusmaht mõõdetuna ehhokardiograafial alla 
200 ml/kg/min. Milrinooni manustati vastavalt eelmises uuringus saadud 
doseerimisskeemile. Kindlaksmääratud ajahetkedel võeti vereanalüüsid ravimi 
plasmakontsentratsioonimääramiseks, saadud andmeid analüüsiti mittelineaar-
sete sega-mõjudega farmakokineetika mudelite abil. Mõõdetud ravimikont-
sentratsioonidega kõige paremini sobiva farmakokineetika mudelit kasutati 
seejärel aja-kontsentratsioonikõverate simuleerimiseks ja leiti optimaalseim 
doseerimisskeem eesmärkkontsentratsiooni 150–250 μg/l saavutamiseks.  
• Prospektiivne uuring dobutamiini farmakokineetikast ja farmakodünaamikast 
kriitlises seisundis vastsündinutel. Uuritavateks olid vastsündinud, kes hospi-
taliseeriti Tartu Ülikooli Kliinikumi või Tallinna Lastehaigla laste- ja vast-
sündinute intensiivraviosakonda nende esimese 72 elutunni jooksul aja-
vahemikul aprill 2016 kuni detsember 2017. Ravi dobutamiiniga alustati 
kliinilisel näidustusel raviarsti otsusel. Ravimit manustati püsiinfusioonina  
5–20 μg/kg/min, doosi tõsteti iga 20–30 minuti järel. Koguti vereanalüüsid 
dobutamiini plasmakontsentratsioonimääramiseks ja salvestati hemodünaa-
mika parameetrid patsiendimonitoridest ja ehhokardiograafial. Saadud and-
meid analüüsiti segamõjudega mitteleneaarsete mudelite abil, kasutades 
samaaegset farmakokineetika ja farmakodünaamika modelleerimist. 
 
Peamised tulemused ja arutelu 
Esimese uuringu populatsioon koosnes 31 vastsündinust, keskmise (vahemik) 
gestatsioonivanusega 26 (23–35) nädalat, sünnijärgse vanusega 13 (3–29) päeva 
ja operatsioonipäeva kehakaaluga 760 (500–2,351) g. Leidsime kirjandusest viis 
milrinooni laste populatsiooni farmakokineetika mudelit, millest neli olid kirjel-
datud kardiokirurgia ja kunstliku vereringe patsientide populatsioonil. Meie 
uuringupopulatsioonile kõige lähem oli esimese 12 elutunni enneaegsete vast-
sündinute populatsioonil kirjeldatud ühekambriline mudel. (Paradisis et al. 2007) 
Mudeli ainukeseks vastsündinu suurust ja küpsust kirjeldavaks kovariaadiks oli 
kehakaal, mille suhtes totaalne kliirens ja suhteline jaotusruumala olid kohan-
datud. Eesmärgiks seatud kontsentratsioonivahemik saavutatakse selle mudeli 
põhjal kõige paremini 0.73 μg/kg/min kolmetunnise küllastusinfusiooni ja sellele 
järgneva 0.16 μg/kg/min säilitusdoosiga. Simulatsiooniuuringuga näitasime, et 
arterioosjuha sulgemise järgses kliinilises situatsioonis on terapeutilise kont-
sentratsiooni saavutamiseks sobivam aeglane e küllastusdoos ja selle järgnev 
säilitusinfusioon kui pideva ühesugune infusioonikiirus kohe manustamise algu-
sest. Leitud doseerimisskeemi kasutasime oma prospektiivses milrinooni farmako-
kineetika uuringus. 
Teise uuringu perioodil tehti kahes uuringukeskuses kokku 21 arterioosjuha 
sulgemise operatsiooni. Nendest 14 patsienti arvati uuringusse, ning omakorda 
10 patsienti said ravi milrinooniga vastavalt protokollile. Nende vastsündinute 
keskmine (vahemik) postmenstruaalne vanus ja kehakaal operatsioonipäeval olid 
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27.4 (24.6–30.1) nädalat ja 857.3 (568.0–1114.0) g. Parima doseerimisskeemi 
leidmiseks tegime järgnevalt simulatsioonid kõikide esimese ja teise uuringu-
perioodi jooksul opereeritud patsientidega, kokku 52 vastsündinuga. Nende 
keskmine (vahemik) postmenstruaalne vanus ja kehakaal olid vastavalt 27.6 
(23.3–37.3) nädalat ja 875.5 (500.0–2351.0) g. Kõige paremini kirjeldas uuringus 
kogutud farmakokineetika andmeid ühekambriline lineaarne mudel, mille 
parameetrid olid allomeetriliselt skaleeritud kehakaalule ning totaalse kliirensi 
arvutamisel arvestatud glomerulaarfiltratsiooni küpsemist vastavalt post-
menstruaalvanusele. Populatsiooni keskmine (inter-individuaalne varieeruvus) 
hinnang milrinooni totaalsele kliirensile ja suhtelisele jaotusruumalale oli vasta-
valt 0.350 l/h/857.3g (11.6%) ja 0.329 l/857.3g (32.6%). Simulatsioonide tule-
musena saame öelda, et parim eesmärkkontsentratsiooni tabamine on saavutatav 
kolmetunnise küllastusinfusiooniga 0.50 μg/kg/min, millele järgneb säilitusdoos 
sõltuvalt postmenstruaalvanusest. Vastsündinutel postmenstruaalses vanuses alla 
27 nädala on sobivaks säilitusdoosiks 0.15 μg/kg/min ja alates 27 nädalast 
0.20 μg/kg/min. Võrreldes esimese elupäeva vastsündinutega (kirjanduse analüüs 
esimeses uuringus) on neil patsientidel väiksem milrinooni suhteline jaotus-
ruumala ja suurem eliminatsioonikiirus, mis on seletatav keha veesisalduse 
languse ja glomerulaarfiltratsiooni kiire tõusuga esimesel elunädalal. Sellest tule-
nevalt on meie mudeli põhjal soovitatud küllastusdoos väiksem ja säilitusannus 
osadel vastsündinutel suurem. 
Dobutamiini farmakokineetika ja farmakodünaamika uuringusse võtsime 31 
vastsündinut, kellest 28 vastsündinu andmeid analüüsisime. Uuringupopulat-
siooni mediaan (vahemik) gestatsioonivanus oli 30.4 (22.7–41.0) nädalat, 
sünnijärgne vanus uuringusse arvamisel 6 (2 – 28) tundi ja sünnikaal 1618 (465–
4380) g. Dobutamiini farmakokineetikat kirjeldasime ühekambrilise lineaarse 
mudeliga, milles parameetrid olid allomeetriliselt skaleeritud kehakaalule ja 
totaalse kliirensi arvutamisel arvestati eliminatsioonimehhanismide küpsemist 
vastavalt postmenstruaalvanusele. Populatsiooni keskmine (inter-individuaalne 
varieeruvus) hinnang dobutamiini totaalsele kliirensile ja suhtelisele jaotus-
ruumalale oli vastavalt 41.2 l/h/1618g (29%) ja 5.29 l/1618g (29%). Kirjeldasime 
dobutamiini kontsentratsioonist sõltuvat toimet südame minutimahule, väljutus-
fraktsioonile, südamesagedusele, keskmisele arteriaalsele vererõhule ja ajukoe 
fraktsionaalne hapnikuekstraktsioonile. Näitasime, et südamesagedus ja vererõhk 
tõusevad dobutamiini toimel vähe, see muutus ilmneb madalatel kontsentrat-
sioonidel ja on küllastuv. Ajukoe fraktsionaalne hapnikuekstraktsioon dobutamiini 
toimel langeb. Sellest võime järeldada, et aju verevool paraneb juba suhteliselt 
madalate dobutamiini kontsentratsioonide juures. Dobutamiini südamefunktsiooni 
ja -minutimahtu suurendav toime jätkub ka kõrgematel, kuni 200 μg/l plasma-
kontsentratsioonidel. 
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Järeldused 
• Simulatsiooniuuring näitas, et enneaegsetel vastsündinutel on milrinooni 
terapeutilise plasmakontsentratsiooni saavutamiseks arterioosjuha sulgemise 
järgselt sobivaim aeglane küllastusdoos järgneva säilitusinfusiooniga. Et 
tabada eesmärkkontsentratsiooni 150– 200 μg/l vähemalt 80% ajast 3–24 
tundi peale ravi alustamist võimalikult paljudel patsientidel, peaksime kasu-
tama kolmetunnist küllastusinfusiooni 0.73 μg/kg/min ja järgnevat säilitus-
doosi 0.16 μg/kg/min. 
• Milrinooni farmakokineetikat vastsündinutel kirjeldab ühekambriline lineaarne 
mudel, mille parameetrid on allomeetriliselt skaleeritud kehakaalule ning 
kliirensi arvutamisel arvestatakse glomerulaarfiltratsiooni vanuselist küpse-
mist. Kiired füsioloogilised muutused esimese elunädala jooksul keha koos-
tises ja neerufunktsioonis mõjutavad milrinooni farmakokineetikat, mistõttu 
on arterioosjuha ligeerimise järgselt ravimi totaalne kliirens suurem ja suhte-
line jaotusruumala väiksem kui enneaegsetel vastsündinutel esimesel elu-
päeval. 
• Modelleerimise ja simulatsioonide tulemusel soovitame arterioosjuha sulge-
mise järgse kardiopulmonaalse seisundi halvenemise vältimiseks doseerimis-
skeemi, mis sõltub postmenstruaalvanusest. Alla 27 nädala vanustel vastsündi-
nutel järgneb kolmetunnisele küllastusinfusioonile 0.50 μg/kg/min säilitusdoos 
0.15 μg/kg/min ja alates 27 nädala vanustest samale küllastusdoosile säilitus-
doos 0.20 μg/kg/min. 
• Dobutamiini farmakokineetikat vastsündinutel kirjeldab ühekambriline 
lineaarne mudel, milles parameetrid on allomeetriliselt skaleeritud kehakaalule 
ja totaalse kliirensi arvutamisel arvestatakse eliminatsioonimehhanismide 
küpsemist vastavalt postmenstruaalvanusele. 
• Dobutamiini toimed südame funktsioonile, vererõhule ja aju verevoolule aval-
duvad erinevate plasmakontsentratsioonide juures. Südamesagedus ja vere-
rõhk tõusevad dobutamiini toimel vähe, see toime ilmneb plasmakontsentrat-
sioonidel alla 100 μg/l ja on küllastuv. Südame funktsioon ja minutimaht 
tõusevad veel ka dobutamiini kõrgemate, kuni 200 μg/l plasmakontsentrat-
sioonide juures.  
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APPENDIX 
 
Figure A1. Basic goodness-of-fit plots of the final dobutamine-right ventricular output 
(RVO) pharmacokinetic-pharmacodynamic model: A observed versus population 
predicted dobutamine plasma concentrations, B observed versus individual predicted 
dobutamine plasma concentrations, C absolute value of individual weighted residuals 
(|iWRES|) versus individual concentration predictions, D conditional weighted residuals 
(CWRES) of concentrations over time (log-scale), E observed versus population predicted 
RVO, F observed versus individual predicted RVO, G absolute value of individual weighted 
residuals (|iWRES|) versus individual RVO predictions, H conditional weighted residuals 
of RVO over time. 
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Figure A2. Basic goodness-of-fit plots of the final dobutamine-left ventricular output 
(LVO) pharmacokinetic-pharmacodynamic model: A observed versus population predicted 
dobutamine plasma concentrations, B observed versus individual predicted dobutamine 
plasma concentrations, C absolute value of individual weighted residuals (|iWRES|) 
versus individual concentration predictions, D conditional weighted residuals (CWRES) 
of concentrations over time (log-scale), E observed versus population predicted LVO, F 
observed versus individual predicted LVO, G absolute value of individual weighted 
residuals (|iWRES|) versus individual LVO predictions, H conditional weighted residuals 
of LVO over time.   
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Figure A3. Basic goodness-of-fit plots of the final dobutamine-left ventricular ejection 
fraction (LVEF) pharmacokinetic-pharmacodynamic model: A observed versus population 
predicted dobutamine plasma concentrations, B observed versus individual predicted 
dobutamine plasma concentrations, C absolute value of individual weighted residuals 
(|iWRES|) versus individual concentration predictions, D conditional weighted residuals 
(CWRES) of concentrations over time (log-scale), E observed versus population predicted 
LVEF, F observed versus individual predicted LVEF, G absolute value of individual 
weighted residuals (|iWRES|) versus individual LVEF predictions, H conditional weighted 
residuals of LVEF over time. 
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Figure A4. Basic goodness-of-fit plots of the final dobutamine-heart rate (HR) 
pharmacokinetic-pharmacodynamic model: A observed versus population predicted 
dobutamine plasma concentrations, B observed versus individual predicted dobutamine 
plasma concentrations, C absolute value of individual weighted residuals (|iWRES|) 
versus individual concentration predictions, D conditional weighted residuals (CWRES) 
of concentrations over time (log-scale), E observed versus population predicted HR, F 
observed versus individual predicted HR, G absolute value of individual weighted 
residuals (|iWRES|) versus individual HR predictions, H conditional weighted residuals 
of HR over time.   
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Figure A5. Basic goodness-of-fit plots of the final dobutamine-mean arterial blood pressure 
(MAP) pharmacokinetic-pharmacodynamic model: A observed versus population predicted 
dobutamine plasma concentrations, B observed versus individual predicted dobutamine 
plasma concentrations, C absolute value of individual weighted residuals (|iWRES|) 
versus individual concentration predictions, D conditional weighted residuals (CWRES) 
of concentrations over time (log-scale), E observed versus population predicted MAP, F 
observed versus individual predicted MAP, G absolute value of individual weighted 
residuals (|iWRES|) versus individual MAP predictions, H conditional weighted residuals 
of MAP over time.   
A
Population predictions (μg /L)
O
bs
er
ve
d 
co
nc
en
tr
at
io
n 
(μ
g/
 L
)
0
100
200
300
0 50 100 150
B
Individual predictions (μg /L)
O
bs
er
ve
d 
co
nc
en
tr
at
io
n 
(μ
g/
 L
)
0
100
200
300
0 50 100 150 200
C
Individual predictions (μg /L)
|iW
R
E
S
|
0.0
0.5
1.0
1.5
2.0
2.5
3.0
0 50 100 150 200
D
Time (h)
C
W
R
E
S
−2
−1
0
1
2
1 10 100
E
Population predictions (mmHg)
O
bs
er
ve
d 
M
A
P
 (
m
m
H
g)
20
30
40
50
60
70
40.0 40.5 41.0 41.5 42.0
F
Individual predictions (mmHG)
O
bs
er
ve
d 
M
A
P
 (
m
m
H
g)
20
30
40
50
60
70
30 40 50 60
G
Individual predictions (mmHG)
|iW
R
E
S
|
0
1
2
3
4
5
30 40 50 60
H
Time (h)
C
W
R
E
S
−4
−2
0
2
0.0 0.5 1.0 1.5 2.0 2.5 3.0
104 
 
Figure A6. Basic goodness-of-fit plots of the final dobutamine-cerebral fractional tissue 
oxygen extraction (cFTOE) pharmacokinetic-pharmacodynamic model: A observed 
versus population predicted dobutamine plasma concentrations, B observed versus 
individual predicted dobutamine plasma concentrations, C absolute value of individual 
weighted residuals (|iWRES|) versus individual concentration predictions, D conditional 
weighted residuals (CWRES) of concentrations over time (log-scale), E observed versus 
population predicted cFTOE, F observed versus individual predicted cFTOE, G absolute 
value of individual weighted residuals (|iWRES|) versus individual cFTOE predictions, 
H conditional weighted residuals of cFTOE over time. 
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